

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
022234Orig1s000

ADMINISTRATIVE and CORRESPONDENCE
DOCUMENTS

EXCLUSIVITY SUMMARY

NDA # 022234

SUPPL #

HFD # 150

Trade Name None

Generic Name Docetaxel Injection, 20 mg/2 mL single dose vial, 80 mg/8 mL multi-dose vial and 160 mg/16 mL multi-dose vial

Applicant Name Hospira, Inc

Approval Date, If Known March 8, 2011

PART I IS AN EXCLUSIVITY DETERMINATION NEEDED?

1. An exclusivity determination will be made for all original applications, and all efficacy supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to one or more of the following questions about the submission.

a) Is it a 505(b)(1), 505(b)(2) or efficacy supplement?

YES NO

b) If yes, what type? Specify 505(b)(1), 505(b)(2), SE1, SE2, SE3, SE4, SE5, SE6, SE7, SE8

505(b)(2)

c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety? (If it required review only of bioavailability or bioequivalence data, answer "no.")

YES NO

If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study.

No study was performed. The Applicant's request to waive the requirement from conducting in vivo studies for NDA 022234, Docetaxel Injection, 10 mg/mL (20 mg/2 mL; 80 mg/8 mL; 160 mg/16 mL) is granted based on the fact that the 10 mg/mL Hospira's Docetaxel for Injection has the same concentration as for the initially diluted Taxotere solution for Injection. Intravenous infusion of the two products will result in an identical amount of drug delivered directly to the systemic circulation.

If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data:

d) Did the applicant request exclusivity?

YES NO

If the answer to (d) is "yes," how many years of exclusivity did the applicant request?

e) Has pediatric exclusivity been granted for this Active Moiety?

YES NO

No pediatric exclusivity has been granted for NDA 022234. Pediatric exclusivity has been granted for the RLD, NDA 020449, Taxotere.

If the answer to the above question in YES, is this approval a result of the studies submitted in response to the Pediatric Written Request?

IF YOU HAVE ANSWERED "NO" TO ALL OF THE ABOVE QUESTIONS, GO DIRECTLY TO THE SIGNATURE BLOCKS AT THE END OF THIS DOCUMENT.

2. Is this drug product or indication a DESI upgrade?

YES NO

IF THE ANSWER TO QUESTION 2 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8 (even if a study was required for the upgrade).

PART II FIVE-YEAR EXCLUSIVITY FOR NEW CHEMICAL ENTITIES

(Answer either #1 or #2 as appropriate)

1. Single active ingredient product.

Has FDA previously approved under section 505 of the Act any drug product containing the same active moiety as the drug under consideration? Answer "yes" if the active moiety (including other esterified forms, salts, complexes, chelates or clathrates) has been previously approved, but this particular form of the active moiety, e.g., this particular ester or salt (including salts with hydrogen or coordination bonding) or other non-covalent derivative (such as a complex, chelate, or clathrate) has not been approved. Answer "no" if the compound requires metabolic conversion (other than deesterification of an esterified form of the drug) to produce an already approved active moiety.

YES NO

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA# 020449 Taxotere

NDA#

NDA#

2. Combination product.

If the product contains more than one active moiety(as defined in Part II, #1), has FDA previously approved an application under section 505 containing any one of the active moieties in the drug product? If, for example, the combination contains one never-before-approved active moiety and one previously approved active moiety, answer "yes." (An active moiety that is marketed under an OTC monograph, but that was never approved under an NDA, is considered not previously approved.)

YES NO

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA#

NDA#

NDA#

IF THE ANSWER TO QUESTION 1 OR 2 UNDER PART II IS "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8. (Caution: The questions in part II of the summary should only be answered "NO" for original approvals of new molecular entities.)
IF "YES," GO TO PART III.

PART III THREE-YEAR EXCLUSIVITY FOR NDAs AND SUPPLEMENTS

To qualify for three years of exclusivity, an application or supplement must contain "reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant." This section should be completed only if the answer to PART II, Question 1 or 2 was "yes."

1. Does the application contain reports of clinical investigations? (The Agency interprets "clinical

investigations" to mean investigations conducted on humans other than bioavailability studies.) If the application contains clinical investigations only by virtue of a right of reference to clinical investigations in another application, answer "yes," then skip to question 3(a). If the answer to 3(a) is "yes" for any investigation referred to in another application, do not complete remainder of summary for that investigation.

YES NO

IF "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. A clinical investigation is "essential to the approval" if the Agency could not have approved the application or supplement without relying on that investigation. Thus, the investigation is not essential to the approval if 1) no clinical investigation is necessary to support the supplement or application in light of previously approved applications (i.e., information other than clinical trials, such as bioavailability data, would be sufficient to provide a basis for approval as an ANDA or 505(b)(2) application because of what is already known about a previously approved product), or 2) there are published reports of studies (other than those conducted or sponsored by the applicant) or other publicly available data that independently would have been sufficient to support approval of the application, without reference to the clinical investigation submitted in the application.

(a) In light of previously approved applications, is a clinical investigation (either conducted by the applicant or available from some other source, including the published literature) necessary to support approval of the application or supplement?

YES NO

If "no," state the basis for your conclusion that a clinical trial is not necessary for approval AND GO DIRECTLY TO SIGNATURE BLOCK ON PAGE 8:

(b) Did the applicant submit a list of published studies relevant to the safety and effectiveness of this drug product and a statement that the publicly available data would not independently support approval of the application?

YES NO

(1) If the answer to 2(b) is "yes," do you personally know of any reason to disagree with the applicant's conclusion? If not applicable, answer NO.

YES NO

If yes, explain:

(2) If the answer to 2(b) is "no," are you aware of published studies not conducted or sponsored by the applicant or other publicly available data that could independently demonstrate the safety and effectiveness of this drug product?

YES NO

If yes, explain:

- (c) If the answers to (b)(1) and (b)(2) were both "no," identify the clinical investigations submitted in the application that are essential to the approval:

Studies comparing two products with the same ingredient(s) are considered to be bioavailability studies for the purpose of this section.

3. In addition to being essential, investigations must be "new" to support exclusivity. The agency interprets "new clinical investigation" to mean an investigation that 1) has not been relied on by the agency to demonstrate the effectiveness of a previously approved drug for any indication and 2) does not duplicate the results of another investigation that was relied on by the agency to demonstrate the effectiveness of a previously approved drug product, i.e., does not redemonstrate something the agency considers to have been demonstrated in an already approved application.

a) For each investigation identified as "essential to the approval," has the investigation been relied on by the agency to demonstrate the effectiveness of a previously approved drug product? (If the investigation was relied on only to support the safety of a previously approved drug, answer "no.")

Investigation #1 YES NO

Investigation #2 YES NO

If you have answered "yes" for one or more investigations, identify each such investigation and the NDA in which each was relied upon:

b) For each investigation identified as "essential to the approval", does the investigation duplicate the results of another investigation that was relied on by the agency to support the effectiveness of a previously approved drug product?

Investigation #1 YES NO

Investigation #2 YES NO

If you have answered "yes" for one or more investigation, identify the NDA in which a similar investigation was relied on:

c) If the answers to 3(a) and 3(b) are no, identify each "new" investigation in the application or supplement that is essential to the approval (i.e., the investigations listed in #2(c), less any that are not "new"):

4. To be eligible for exclusivity, a new investigation that is essential to approval must also have been conducted or sponsored by the applicant. An investigation was "conducted or sponsored by" the applicant if, before or during the conduct of the investigation, 1) the applicant was the sponsor of the IND named in the form FDA 1571 filed with the Agency, or 2) the applicant (or its predecessor in interest) provided substantial support for the study. Ordinarily, substantial support will mean providing 50 percent or more of the cost of the study.

a) For each investigation identified in response to question 3(c): if the investigation was carried out under an IND, was the applicant identified on the FDA 1571 as the sponsor?

Investigation #1 !
IND # YES ! NO
! Explain:

Investigation #2 !
IND # YES ! NO
! Explain:

(b) For each investigation not carried out under an IND or for which the applicant was not identified as the sponsor, did the applicant certify that it or the applicant's predecessor in interest provided substantial support for the study?

Investigation #1 !
YES ! NO
Explain: ! Explain:

Investigation #2 !

YES

Explain:

!

! NO

! Explain:

(c) Notwithstanding an answer of "yes" to (a) or (b), are there other reasons to believe that the applicant should not be credited with having "conducted or sponsored" the study? (Purchased studies may not be used as the basis for exclusivity. However, if all rights to the drug are purchased (not just studies on the drug), the applicant may be considered to have sponsored or conducted the studies sponsored or conducted by its predecessor in interest.)

YES

NO

If yes, explain:

Name of person completing form: Frank Cross, Jr.

Title: CPMS

Date: March 17, 2011

Name of Office/Division Director signing form:

Robert L. Justice, M.D., M.S.

Title: Director, Division of Drug Oncology Products

Form OGD-011347; Revised 05/10/2004; formatted 2/15/05

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

FRANK H CROSS
03/17/2011

ROBERT L JUSTICE
03/17/2011



1.3.3 Debarment Certification

As required under Section 306(k)(1) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 335a(k)), a signed certification statement from Hospira, Inc. is provided herein.



Debarment Certification


Docetaxel Injection

Section 306(k) of the Federal Food, Drug and Cosmetic Act (the Act) (21 U.S.C. 335a(k)) requires that:

"Any application for approval of a drug product shall include

- (1) a certification that the applicant did not and will not use in any capacity the services of any person debarred under subsection (a) or (b) in connection with such application

Hospira, Inc. hereby certifies that it did not and will not use, in any capacity, the services of any person debarred under section 306 of the Act in connection with this application.



Judith Zutkis
Director, Global Regulatory Affairs
Hospira, Inc.
275 North Field Drive
Dept. 0389, Bldg. H2
Lake Forest, IL 60045-5046

6/22/2007
Date

ACTION PACKAGE CHECKLIST

APPLICATION INFORMATION ¹		
NDA # 22-234 BLA #	NDA Supplement # BLA STN #	If NDA, Efficacy Supplement Type:
Proprietary Name: Established/Proper Name: Docetaxel Dosage Form: Injection, 20 mg/2 mL single-dose vial 80 mg/8 mL multi-dose vial 160 mg/16 mL multi-dose vial		Applicant: Hospira, Inc. Agent for Applicant (if applicable):
RPM: Cross		Division: DDOP

¹ The **Application Information** section is (only) a checklist. The **Contents of Action Package** section (beginning on page 5) lists the documents to be included in the Action Package.

NDA Application Type: 505(b)(1) 505(b)(2)
Efficacy Supplement: 505(b)(1) 505(b)(2)

505(b)(2) Original NDAs and 505(b)(2) NDA supplements:
Listed drug(s) referred to in 505(b)(2) application (include NDA/ANDA #(s) and drug name(s)):

(A supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2). Consult page 1 of the NDA Regulatory Filing Review for this application or Appendix A to this Action Package Checklist.)

NDA 20-449, TAXOTERE® (docetaxel) Injection Concentrate, 20 mg and 80mg.

Provide a brief explanation of how this product is different from the listed drug.

This is a 505(b)(2) application for docetaxel injection submitted by Hospira, Inc. The major differences between Sanofi-Aventis' Taxotere® and Hospira's product are as follows:

- a) The Hospira product can be directly diluted into infusion solutions, as compared to Taxotere®, which must be diluted to a strength of 10 mg/mL prior to addition into infusion solutions.
- b) Hospira, Inc. is registering an additional presentation (160 mg/16 mL) that the innovator does not have.
- c) Hospira, Inc. is proposing a multi-dose application for the 80 mg/8 mL and 160 mg/16mL presentations as compared to Taxotere® which is supplied as single-dose vials.

If no listed drug, check here and explain:

Prior to approval, review and confirm the information previously provided in Appendix B to the Regulatory Filing Review by re-checking the Orange Book for any new patents and pediatric exclusivity. If there are any changes in patents or exclusivity, notify the OND ADRA immediately and complete a new Appendix B of the Regulatory Filing Review.

No changes Updated
Date of check: August 11, 2008

If pediatric exclusivity has been granted or the pediatric information in the labeling of the listed drug changed, determine whether pediatric information needs to be added to or deleted from the labeling of this drug.

On the day of approval, check the Orange Book again for any new patents or pediatric exclusivity.

❖ User Fee Goal Date
Action Goal Date (if different)

August 11, 2008

❖ Actions

- Proposed action
- Previous actions (*specify type and date for each action taken*)

AP	TA	AE
NA	CR	

None

❖ Advertising (*approvals only*)
Note: If accelerated approval (21 CFR 314.510/601.41), advertising MUST have been submitted and reviewed (*indicate dates of reviews*)

Requested in AP letter
Received and reviewed
N/A

❖ Application² Characteristics

Review priority: Standard Priority
Chemical classification (new NDAs only):

Fast Track
Rolling Review
Orphan drug designation

Rx-to-OTC full switch
Rx-to-OTC partial switch
Direct-to-OTC

NDAs: Subpart H

Accelerated approval (21 CFR 314.510)
Restricted distribution (21 CFR 314.520)

Subpart I

Approval based on animal studies

BLAs: Subpart E

Accelerated approval (21 CFR 601.41)
Restricted distribution (21 CFR 601.42)

Subpart H

Approval based on animal studies

Submitted in response to a PMR
Submitted in response to a PMC

Comments:

❖ Application Integrity Policy (AIP) http://www.fda.gov/ora/compliance_ref/aip_page.html

• Applicant is on the AIP	Yes	No
• This application is on the AIP	Yes	No
• If yes, exception for review granted (<i>file Center Director's memo in Administrative/Regulatory Documents section, with Administrative Reviews</i>)	Yes	
• If yes, OC clearance for approval (<i>file communication in Administrative/Regulatory Documents section with Administrative Reviews</i>)	Yes	Not an AP action
❖ Date reviewed by PeRC (<i>required for approvals only</i>) If PeRC review not necessary, explain:		
❖ BLAs only: <i>RMS-BLA Product Information Sheet for TBP</i> has been completed and forwarded to OBPS/DRM (<i>approvals only</i>)	Yes, date	
❖ BLAs only: is the product subject to official FDA lot release per 21 CFR 610.2 (<i>approvals only</i>)	Yes	No
❖ Public communications (<i>approvals only</i>)		
• Office of Executive Programs (OEP) liaison has been notified of action	Yes	No
• Press Office notified of action	Yes	No
• Indicate what types (if any) of information dissemination are anticipated	None HHS Press Release FDA Talk Paper CDER Q&As Other	

² All questions in all sections pertain to the pending application, i.e., if the pending application is an NDA or BLA supplement, then the questions should be answered in relation to that supplement, not in relation to the original NDA or BLA. For example, if the application is a pending BLA supplement, then a new *RMS-BLA Product Information Sheet for TBP* must be completed.

❖ Exclusivity

<ul style="list-style-type: none"> Is approval of this application blocked by any type of exclusivity? 	No	Yes
<ul style="list-style-type: none"> NDA and BLAs: Is there existing orphan drug exclusivity for the “same” drug or biologic for the proposed indication(s)? <i>Refer to 21 CFR 316.3(b)(13) for the definition of “same drug” for an orphan drug (i.e., active moiety). This definition is NOT the same as that used for NDA chemical classification.</i> 	No	Yes If, yes, NDA/BLA # and date exclusivity expires:
<ul style="list-style-type: none"> (b)(2) NDAs only: Is there remaining 5-year exclusivity that would bar effective approval of a 505(b)(2) application? <i>(Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.)</i> 	No	Yes If yes, NDA # and date exclusivity expires:
<ul style="list-style-type: none"> (b)(2) NDAs only: Is there remaining 3-year exclusivity that would bar effective approval of a 505(b)(2) application? <i>(Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.)</i> 	No	Yes If yes, NDA # 20-449 and date exclusivity expires: 3/22/09; 10/17/09
<ul style="list-style-type: none"> (b)(2) NDAs only: Is there remaining 6-month pediatric exclusivity that would bar effective approval of a 505(b)(2) application? <i>(Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.)</i> 	No	Yes If yes, NDA # and date exclusivity expires:
<ul style="list-style-type: none"> NDAs only: Is this a single enantiomer that falls under the 10-year approval limitation of 505(u)? <i>(Note that, even if the 10-year approval limitation period has not expired, the application may be tentatively approved if it is otherwise ready for approval.)</i> 	No	Yes If yes, NDA # and date 10-year limitation expires:

❖ Patent Information (NDAs only)

<ul style="list-style-type: none"> Patent Information: Verify that form FDA-3542a was submitted for patents that claim the drug for which approval is sought. If the drug is an old antibiotic, skip the Patent Certification questions. 	Verified	Not applicable because drug is an old antibiotic.
<ul style="list-style-type: none"> Patent Certification [505(b)(2) applications]: Verify that a certification was submitted for each patent for the listed drug(s) in the Orange Book and identify the type of certification submitted for each patent. 	21 CFR 314.50(i)(1)(i)(A) Verified	
<ul style="list-style-type: none"> [505(b)(2) applications] If the application includes a paragraph III certification, it cannot be approved until the date that the patent to which the certification pertains expires (but may be tentatively approved if it is otherwise ready for approval). 		No paragraph III certification Date patent will expire 9/28/10
<ul style="list-style-type: none"> [505(b)(2) applications] For each paragraph IV certification, verify that the applicant notified the NDA holder and patent owner(s) of its certification that the patent(s) is invalid, unenforceable, or will not be infringed (review documentation of notification by applicant and documentation of receipt of notice by patent owner and NDA holder). <i>(If the application does not include any paragraph IV certifications, mark “N/A” and skip to the next section below (Summary Reviews)).</i> 	N/A (no paragraph IV certification) Verified	

- [505(b)(2) applications] For **each paragraph IV** certification, based on the questions below, determine whether a 30-month stay of approval is in effect due to patent infringement litigation.

Answer the following questions for **each** paragraph IV certification:

- | | | |
|--|-----|----|
| (1) Have 45 days passed since the patent owner's receipt of the applicant's notice of certification? | Yes | No |
|--|-----|----|

(Note: The date that the patent owner received the applicant's notice of certification can be determined by checking the application. The applicant is required to amend its 505(b)(2) application to include documentation of this date (e.g., copy of return receipt or letter from recipient acknowledging its receipt of the notice) (see 21 CFR 314.52(e)).

If "Yes," skip to question (4) below. If "No," continue with question (2).

- | | | |
|--|-----|----|
| (2) Has the patent owner (or NDA holder, if it is an exclusive patent licensee) submitted a written waiver of its right to file a legal action for patent infringement after receiving the applicant's notice of certification, as provided for by 21 CFR 314.107(f)(3)? | Yes | No |
|--|-----|----|

If "Yes," there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip the rest of the patent questions.

If "No," continue with question (3).

- | | | |
|---|-----|----|
| (3) Has the patent owner, its representative, or the exclusive patent licensee filed a lawsuit for patent infringement against the applicant? | Yes | No |
|---|-----|----|

(Note: This can be determined by confirming whether the Division has received a written notice from the (b)(2) applicant (or the patent owner or its representative) stating that a legal action was filed within 45 days of receipt of its notice of certification. The applicant is required to notify the Division in writing whenever an action has been filed within this 45-day period (see 21 CFR 314.107(f)(2)).

If "No," the patent owner (or NDA holder, if it is an exclusive patent licensee) has until the expiration of the 45-day period described in question (1) to waive its right to bring a patent infringement action or to bring such an action. After the 45-day period expires, continue with question (4) below.

- | | | |
|--|-----|----|
| (4) Did the patent owner (or NDA holder, if it is an exclusive patent licensee) submit a written waiver of its right to file a legal action for patent infringement within the 45-day period described in question (1), as provided for by 21 CFR 314.107(f)(3)? | Yes | No |
|--|-----|----|

If "Yes," there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip to the next section below (Summary Reviews).

If "No," continue with question (5).

- | | | |
|---|-----|----|
| (5) Did the patent owner, its representative, or the exclusive patent licensee bring suit against the (b)(2) applicant for patent infringement within 45 days of the patent owner's receipt of the applicant's notice of certification? | Yes | No |
|---|-----|----|

(Note: This can be determined by confirming whether the Division has received a written notice from the (b)(2) applicant (or the patent owner or its representative) stating that a legal action was filed within 45 days of receipt of its notice of certification. The applicant is required to notify the Division in writing whenever an action has been filed within this 45-day period (see 21 CFR 314.107(f)(2)). If no written notice appears in the NDA file, confirm with the applicant whether a lawsuit was commenced within the 45-day period).

If "No," there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip to the next section below (Summary Reviews).

If "Yes," a stay of approval may be in effect. To determine if a 30-month stay is in effect, consult with the OND ADRA and attach a summary of the response.

CONTENTS OF ACTION PACKAGE

❖ Copy of this Action Package Checklist ³	Yes
Officer/Employee List	
❖ List of officers/employees who participated in the decision to approve this application and consented to be identified on this list (<i>approvals only</i>)	Included
Documentation of consent/nonconsent by officers/employees	Included
Action Letters	
❖ Copies of all action letters (<i>including approval letter with final labeling</i>)	Action(s) and date(s)
Labeling	
❖ Package Insert (<i>write submission/communication date at upper right of first page of PI</i>)	
❖ Most recent division-proposed labeling (only if generated after latest applicant submission of labeling)	8/11/08
❖ Most recent submitted by applicant labeling (only if subsequent division labeling does not show applicant version)	
❖ Original applicant-proposed labeling	7/9/07
❖ Other relevant labeling (e.g., most recent 3 in class, class labeling), if applicable	
❖ Medication Guide/Patient Package Insert/Instructions for Use (<i>write submission/communication date at upper right of first page of each piece</i>)	Medication Guide Patient Package Insert Instructions for Use None
❖ Most-recent division-proposed labeling (only if generated after latest applicant submission of labeling)	

³ Fill in blanks with dates of reviews, letters, etc.
Version: 5/29/08

❖ Most recent submitted by applicant labeling (only if subsequent division labeling does not show applicant version)	
❖ Original applicant-proposed labeling	7/9/07
❖ Other relevant labeling (e.g., most recent 3 in class, class labeling), if applicable	
❖ Labels (full color carton and immediate-container labels) (<i>write submission/communication date at upper right of first page of each submission</i>)	
❖ Most-recent division proposal for (only if generated after latest applicant submission)	
❖ Most recent applicant-proposed labeling	8/11/08
❖ Labeling reviews (<i>indicate dates of reviews and meetings</i>)	RPM DMEDP DRISK DDMAC CSS Other reviews SEALD
Administrative / Regulatory Documents	
❖ Administrative Reviews (e.g., RPM Filing Review ⁴ /Memo of Filing Meeting) (<i>indicate date of each review</i>)	8/11/07
❖ NDAs only: Exclusivity Summary (<i>signed by Division Director</i>)	Included
❖ AIP-related documents <ul style="list-style-type: none"> Center Director's Exception for Review memo If approval action, OC clearance for approval 	Not on AIP
❖ Pediatric Page (<i>approvals only, must be reviewed by PERC before finalized</i>)	Included
❖ Debarment certification (original applications only): verified that qualifying language was not used in certification and that certifications from foreign applicants are cosigned by U.S. agent (<i>include certification</i>)	Verified, statement is acceptable
❖ Postmarketing Requirement (PMR) Studies	None
<ul style="list-style-type: none"> Outgoing communications (<i>if located elsewhere in package, state where located</i>) Incoming submissions/communications 	
❖ Postmarketing Commitment (PMC) Studies	None
<ul style="list-style-type: none"> Outgoing Agency request for postmarketing commitments (<i>if located elsewhere in package, state where located</i>) Incoming submission documenting commitment 	
❖ Outgoing communications (<i>letters (except previous action letters), emails, faxes, telecons</i>)	Yes
❖ Internal memoranda, telecons, etc.	
❖ Minutes of Meetings	
<ul style="list-style-type: none"> Pre-Approval Safety Conference (<i>indicate date; approvals only</i>) Regulatory Briefing (<i>indicate date</i>) Pre-NDA/BLA meeting (<i>indicate date</i>) EOP2 meeting (<i>indicate date</i>) Other (e.g., EOP2a, CMC pilot programs) 	Not applicable No mtg No mtg No mtg None

⁴ Filing reviews for other disciplines should be filed behind the discipline tab.
Version: 5/29/08

❖ Advisory Committee Meeting(s)	No AC meeting
<ul style="list-style-type: none"> Date(s) of Meeting(s) 48-hour alert or minutes, if available 	

Decisional and Summary Memos

❖ Office Director Decisional Memo (<i>indicate date for each review</i>)	None
Division Director Summary Review (<i>indicate date for each review</i>)	None 8/11/08
Cross-Discipline Team Leader Review (<i>indicate date for each review</i>)	None 8/11/08

Clinical Information⁵

❖ Clinical Reviews	
<ul style="list-style-type: none"> Clinical Team Leader Review(s) (<i>indicate date for each review</i>) Clinical review(s) (<i>indicate date for each review</i>) Social scientist review(s) (if OTC drug) (<i>indicate date for each review</i>) 	8/11/08 8/7/08 None
❖ Safety update review(s) (<i>indicate location/date if incorporated into another review</i>)	8/7/08
❖ Financial Disclosure reviews(s) or location/date if addressed in another review OR If no financial disclosure information was required, review/memo explaining why not	8/7/08
❖ Clinical reviews from other clinical areas/divisions/Centers (<i>indicate date of each review</i>)	None
❖ Controlled Substance Staff review(s) and Scheduling Recommendation (<i>indicate date of each review</i>)	Not needed
❖ REMS <ul style="list-style-type: none"> REMS Document and Supporting Statement (<i>indicate date(s) of submission(s)</i>) Review(s) and recommendations (including those by OSE and CSS) (<i>indicate location/date if incorporated into another review</i>) 	None
❖ DSI Inspection Review Summary(ies) (<i>include copies of DSI letters to investigators</i>)	None requested
<ul style="list-style-type: none"> Clinical Studies Bioequivalence Studies Clinical Pharmacology Studies 	

Clinical Microbiology None

❖ Clinical Microbiology Team Leader Review(s) (<i>indicate date for each review</i>)	None
Clinical Microbiology Review(s) (<i>indicate date for each review</i>)	None

Biostatistics None

❖ Statistical Division Director Review(s) (<i>indicate date for each review</i>)	None
Statistical Team Leader Review(s) (<i>indicate date for each review</i>)	None
Statistical Review(s) (<i>indicate date for each review</i>)	None

Clinical Pharmacology None

❖ Clinical Pharmacology Division Director Review(s) (<i>indicate date for each review</i>)	None
Clinical Pharmacology Team Leader Review(s) (<i>indicate date for each review</i>)	None

⁵ Filing reviews should be filed with the discipline reviews.
Version: 5/29/08

Clinical Pharmacology review(s) (<i>indicate date for each review</i>)	None	10/1/07; 4/24/08
❖ DSI Clinical Pharmacology Inspection Review Summary	None	
Nonclinical	None	
❖ Pharmacology/Toxicology Discipline Reviews		
• ADP/T Review(s) (<i>indicate date for each review</i>)	None	
• Supervisory Review(s) (<i>indicate date for each review</i>)	None	
• Pharm/tox review(s), including referenced IND reviews (<i>indicate date for each review</i>)	None	6/9/08
❖ Review(s) by other disciplines/divisions/Centers requested by P/T reviewer (<i>indicate date for each review</i>)	None	
❖ Statistical review(s) of carcinogenicity studies (<i>indicate date for each review</i>)	No carc	
❖ ECAC/CAC report/memo of meeting	None	Included in P/T review, page
❖ DSI Nonclinical Inspection Review Summary	None requested	
CMC/Quality	None	
❖ CMC/Quality Discipline Reviews		
• ONDQA/OBP Division Director Review(s) (<i>indicate date for each review</i>)	None	
• Branch Chief/TeamLeader Review(s) (<i>indicate date for each review</i>)	None	
• CMC/product quality review(s) (<i>indicate date for each review</i>)	None	9/6/07; 7/24/08
• BLAs only: Facility information review(s) (<i>indicate dates</i>)	None	
❖ Microbiology Reviews		
• NDAs: Microbiology reviews (sterility & pyrogenicity) (<i>indicate date of each review</i>)	4/11/08; 6/9/08	Not needed
• BLAs: Sterility assurance, product quality microbiology		
❖ Reviews by other disciplines/divisions/Centers requested by CMC/quality reviewer (<i>indicate date for each review</i>)	None	
❖ Environmental Assessment (check one) (original and supplemental applications)		
Categorical Exclusion (<i>indicate review date</i>)(<i>all original applications and all efficacy supplements that could increase the patient population</i>)	7/24/08	
Review & FONSI (<i>indicate date of review</i>)		
Review & Environmental Impact Statement (<i>indicate date of each review</i>)		
❖ Facilities Review/Inspection		
• NDAs: Facilities inspections (include EER printout) (<i>date completed must be within 2 years of action date</i>)	Date completed: 6/20/08	Acceptable Withhold recommendation
• BLAs:		
➤ TBP-EER	Date completed:	Acceptable Withhold recommendation
➤ Compliance Status Check (approvals only, both original and all supplemental applications except CBEs) (<i>date completed must be within 60 days prior to AP</i>)	Date completed:	Requested Accepted Hold

❖ NDAs: Methods Validation

- Completed
- Requested
- Not yet requested
- Not needed

Appendix A to Action Package Checklist

An NDA or NDA supplemental application is likely to be a 505(b)(2) application if:

- (1) It relies on published literature to meet any of the approval requirements, and the applicant does not have a written right of reference to the underlying data. If published literature is cited in the NDA but is not necessary for approval, the inclusion of such literature will not, in itself, make the application a 505(b)(2) application.
- (2) **Or** it relies for approval on the Agency's previous findings of safety and efficacy for a listed drug product and the applicant does not own or have right to reference the data supporting that approval.
- (3) **Or** it relies on what is "generally known" or "scientifically accepted" about a class of products to support the safety or effectiveness of the particular drug for which the applicant is seeking approval. (Note, however, that this does not mean *any* reference to general information or knowledge (e.g., about disease etiology, support for particular endpoints, methods of analysis) causes the application to be a 505(b)(2) application.)

Types of products for which 505(b)(2) applications are likely to be submitted include: fixed-dose combination drug products (e.g., heart drug and diuretic (hydrochlorothiazide) combinations); OTC monograph deviations (see 21 CFR 330.11); new dosage forms; new indications; and, new salts.

An efficacy supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2).

An efficacy supplement is a 505(b)(1) supplement if the supplement contains all of the information needed to support the approval of the change proposed in the supplement. For example, if the supplemental application is for a new indication, the supplement is a 505(b)(1) if:

- (1) The applicant has conducted its own studies to support the new indication (or otherwise owns or has right of reference to the data/studies).
- (2) **And** no additional information beyond what is included in the supplement or was embodied in the finding of safety and effectiveness for the original application or previously approved supplements is needed to support the change. For example, this would likely be the case with respect to safety considerations if the dose(s) was/were the same as (or lower than) the original application.
- (3) **And** all other "criteria" are met (e.g., the applicant owns or has right of reference to the data relied upon for approval of the supplement, the application does not rely for approval on published literature based on data to which the applicant does not have a right of reference).

An efficacy supplement is a 505(b)(2) supplement if:

- (1) Approval of the change proposed in the supplemental application would require data beyond that needed to support our previous finding of safety and efficacy in the approval of the original application (or earlier supplement), and the applicant has not conducted all of its own studies for approval of the change, or obtained a right to reference studies it does not own. For example, if the change were for a new indication AND a higher dose, we would likely require clinical efficacy data and preclinical safety data to approve the higher dose. If the applicant provided the effectiveness data, but had to rely on a different listed drug, or a new aspect of a previously cited listed drug, to support the safety of the new dose, the supplement would be a 505(b)(2).
- (2) **Or** the applicant relies for approval of the supplement on published literature that is based on data that the applicant does not own or have a right to reference. If published literature is cited in the supplement but is not necessary for approval, the inclusion of such literature will not, in itself, make the supplement a 505(b)(2) supplement.
- (3) **Or** the applicant is relying upon any data they do not own or to which they do not have right of reference.

If you have questions about whether an application is a 505(b)(1) or 505(b)(2) application, consult with your ODE's ADRA.

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Frank Cross

8/11/2008 05:51:52 PM

505(b)(2) ASSESSMENT

Application Information		
NDA # 022234	NDA Supplement #: S-	Efficacy Supplement Type SE-
Proprietary Name: Docetaxel Injection Established/Proper Name: docetaxel Dosage Form: Injectable Strengths: 10 mg/mL (20 mg/2 mL; 80 mg/8 mL; 160 mg/16 mL)		
Applicant: Hospira, Inc		
Date of Receipt: 9/23/10 (Class 2 Resubmission requesting conversion of Tentative Approval to Full Approval) 2 TA Letters previously sent dated 8/11/08 and 12/11/09		
PDUFA Goal Date: 3/23/11		Action Goal Date (if different): 3/23/11
Proposed Indications: <ul style="list-style-type: none">• Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC• Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC• Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer		

GENERAL INFORMATION

1) Is this application for a recombinant or biologically-derived product and/or protein or peptide product *OR* is the applicant relying on a recombinant or biologically-derived product and/or protein or peptide product to support approval of the proposed product?

YES NO

If "YES" contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.



**INFORMATION PROVIDED VIA RELIANCE
(LISTED DRUG OR LITERATURE)**

- 2) List the information essential to the approval of the proposed drug that is provided by reliance on our previous finding of safety and efficacy for a listed drug or by reliance on published literature. *(If not clearly identified by the applicant, this information can usually be derived from annotated labeling.)*

Source of information* (e.g., published literature, name of referenced product)	Information provided (e.g., pharmacokinetic data, or specific sections of labeling)
Taxotere (docetaxel) Injection Concentrate, Intravenous Infusion (IV) 80 mg/2 mL and 20 mg/0.5 mL.	Approved Labeling for NDA 020449

*each source of information should be listed on separate rows

- 3) Reliance on information regarding another product (whether a previously approved product or from published literature) must be scientifically appropriate. An applicant needs to provide a scientific “bridge” to demonstrate the relationship of the referenced and proposed products. Describe how the applicant bridged the proposed product to the referenced product(s). (Example: BA/BE studies)

The Applicant’s request to waive the requirement from conducting in vivo studies for NDA 022234, Docetaxel Injection, 10 mg/mL (20 mg/2 mL; 80 mg/8 mL; 160 mg/16 mL) is granted based on the fact that the 10 mg/mL Hospira’s Docetaxel for Injection has the same concentration as for the initially diluted Taxotere solution for Injection. Intravenous infusion of the two products will result in an identical amount of drug delivered directly to the systemic circulation.

RELIANCE ON PUBLISHED LITERATURE

- 4) (a) Regardless of whether the applicant has explicitly stated a reliance on published literature to support their application, is reliance on published literature necessary to support the approval of the proposed drug product (i.e., the application *cannot* be approved without the published literature)?

YES NO

If “NO,” proceed to question #5.

- (b) Does any of the published literature necessary to support approval identify a specific (e.g., brand name) *listed* drug product?

YES NO

If “NO,” proceed to question #5.

If “YES”, list the listed drug(s) identified by name and answer question #4(c).

- (c) Are the drug product(s) listed in (b) identified by the applicant as the listed drug(s)?

YES NO

RELIANCE ON LISTED DRUG(S)

Reliance on published literature which identifies a specific approved (listed) drug constitutes reliance on that listed drug. Please answer questions #5-9 accordingly.

- 5) Regardless of whether the applicant has explicitly referenced the listed drug(s), does the application **rely** on the finding of safety and effectiveness for one or more listed drugs (approved drugs) to support the approval of the proposed drug product (i.e., the application cannot be approved without this reliance)?

YES NO

If "NO," proceed to question #10.

- 6) Name of listed drug(s) relied upon, and the NDA/ANDA #(s). Please indicate if the applicant explicitly identified the product as being relied upon (see note below):

Name of Drug	NDA/ANDA #	Did applicant specify reliance on the product? (Y/N)
Taxotere (docetaxel) Injection Concentrate, Intravenous Infusion (IV) 80 mg/2 mL and 20 mg/0.5 mL.	020449	Y

Applicants should specify reliance on the 356h, in the cover letter, and/or with their patent certification/statement. If you believe there is reliance on a listed product that has not been explicitly identified as such by the applicant, please contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

- 7) If this is a (b)(2) supplement to an original (b)(2) application, does the supplement rely upon the same listed drug(s) as the original (b)(2) application?

N/A YES NO

If this application is a (b)(2) supplement to an original (b)(1) application or not a supplemental application, answer "N/A".

If "NO", please contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

- 8) Were any of the listed drug(s) relied upon for this application:

- a) Approved in a 505(b)(2) application?

YES NO

If "YES", please list which drug(s).

Name of drug(s) approved in a 505(b)(2) application:

- b) Approved by the DESI process?

YES NO

If "YES", please list which drug(s).

Name of drug(s) approved via the DESI process:

- c) Described in a monograph?

YES NO

If "YES", please list which drug(s).

Name of drug(s) described in a monograph:

d) Discontinued from marketing?

YES NO

If “YES”, please list which drug(s) and answer question d) i. below.

If “NO”, proceed to question #9.

Name of drug(s) discontinued from marketing:

i) Were the products discontinued for reasons related to safety or effectiveness?

YES NO

(Information regarding whether a drug has been discontinued from marketing for reasons of safety or effectiveness may be available in the Orange Book. Refer to section 1.11 for an explanation, and section 6.1 for the list of discontinued drugs. If a determination of the reason for discontinuation has not been published in the Federal Register (and noted in the Orange Book), you will need to research the archive file and/or consult with the review team. Do not rely solely on any statements made by the sponsor.)

9) Describe the change from the listed drug(s) relied upon to support this (b)(2) application (for example, “This application provides for a new indication, otitis media” or “This application provides for a change in dosage form, from capsule to solution”).

- **Product Presentations**

Hospira offers 3 presentations while Sanofi offers only 2. The 160 mg presentation is a presentation unique to Hospira. Please reference the table below for a comparison.

Hospira 1-vial	Taxotere 2-vial	Taxotere 1-vial
20 mg / 2 mL	20 mg / 0.5 mL	20 mg / 1 mL
80 mg / 8 mL	80 mg / 2 mL	80 mg / 4 mL
160 mg / 16 mL	N/A	N/A

- **Product Concentration**

The concentration of all 3 of Hospira’s presentation is 10 mg/mL. For comparison, the Taxotere 1-vial products have concentrations of 20 mg/mL. Their 2-vial products have a concentration for the Concentrate of 40 mg/mL, but once mixed with the diluent supplied the concentration is 10 mg/mL (reference Section 2.8 of Taxotere’s Package Insert).

- **Multi-dose vs. Single-dose**

Hospira has performed studies to qualify the 2 larger presentations (80 mg and 160 mg) as multi-dose vials. Taxotere’s approved products are single-use vials.

- **Formulation**

Hospira's formulation differs from the RLD. Please reference the table below for a comparison.

Ingredient	Hospira 1-vial	Taxotere 2-vial	Taxotere 1-vial
Docetaxel	10 mg/mL	40 mg/mL	20 mg/mL
Polysorbate 80	260 mg/mL	1040 mg/mL	0.54 g/mL
Ethanol	23% v/v	13%*	0.395 g/mL
Citric Acid	4 mg/mL	N/A	N/A
PEG 300	q.s.	N/A	N/A

*Note that the ethanol solution is a 13% (w/w) solution in water for injection and is supplied in a diluent vial separate from the Taxotere concentrate solution.

The purpose of the following two questions is to determine if there is an approved drug product that is equivalent or very similar to the product proposed for approval that should be referenced as a listed drug in the pending application.

*The assessment of pharmaceutical equivalence for a recombinant or biologically-derived product and/or protein or peptide product is complex. If you answered **YES to question #1**, proceed to question #12; if you answered **NO to question #1**, proceed to question #10 below.*

10) (a) Is there a pharmaceutical equivalent(s) to the product proposed in the 505(b)(2) application that is already approved (via an NDA or ANDA)?

*(Pharmaceutical equivalents are drug products in identical dosage forms that: (1) contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified release dosage forms that require a reservoir or overage or such forms as prefilled syringes where residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; (2) do not necessarily contain the same inactive ingredients; **and** (3) meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates. (21 CFR 320.1(c)).*

Note that for proposed combinations of one or more previously approved drugs, a pharmaceutical equivalent must also be a combination of the same drugs.

YES NO

If "NO" to (a) proceed to question #11.

If "YES" to (a), answer (b) and (c) then proceed to question #12.

(b) Is the pharmaceutical equivalent approved for the same indication for which the 505(b)(2) application is seeking approval?

YES NO

(c) Is the listed drug(s) referenced by the application a pharmaceutical equivalent?

YES NO

If “**YES**” to (c) and there are no additional pharmaceutical equivalents listed, proceed to question #12.

If “**NO**” or if there are additional pharmaceutical equivalents that are not referenced by the application, list the NDA pharmaceutical equivalent(s); you do not have to individually list all of the products approved as ANDAs, but please note below if approved generics are listed in the Orange Book. Please also contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

Pharmaceutical equivalent(s):

11) (a) Is there a pharmaceutical alternative(s) already approved (via an NDA or ANDA)?

(Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form or as the same salt or ester. Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times and/or dissolution rates. (21 CFR 320.1(d)) Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate- or standard-release formulations of the same active ingredient.)

Note that for proposed combinations of one or more previously approved drugs, a pharmaceutical alternative must also be a combination of the same drugs.

YES NO

If “**NO**”, proceed to question #12.

(b) Is the pharmaceutical alternative approved for the same indications for which the 505(b)(2) application is seeking approval?

YES NO

(c) Is the approved pharmaceutical alternative(s) referenced as the listed drug(s)?

YES NO

If “**YES**” and there are no additional pharmaceutical alternatives listed, proceed to question #12.

If “**NO**” or if there are additional pharmaceutical alternatives that are not referenced by the application, list the NDA pharmaceutical alternative(s); you do not have to individually list all of the products approved as ANDAs, but please note below if approved generics are listed in the Orange Book. Please also contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

Pharmaceutical alternative(s): Taxotere (docetaxel) Injection Concentrate, Intravenous Infusion (IV) 80 mg/2 mL and 20 mg/0.5 mL.

PATENT CERTIFICATION/STATEMENTS
--

- 12) List the patent numbers of all unexpired patents listed in the Orange Book for the listed drug(s) for which our finding of safety and effectiveness is relied upon to support approval of the (b)(2) product.

<i>Listed drug/Patent number(s):</i>	5698582 (7/3/12)	5698582*PED (1/3/13)
	5714512 (7/3/12)	5714512*PED (1/3/13)
	5750561 (7/3/12)	5750561*PED (1/3/13)
	5438072 (11/22/13)	5438072*PED (5/22/14)

No patents listed *proceed to question #14*

- 13) Did the applicant address (with an appropriate certification or statement) all of the unexpired patents listed in the Orange Book for the listed drug(s) relied upon to support approval of the (b)(2) product?

YES NO

If "NO", list which patents (and which listed drugs) were not addressed by the applicant.

Listed drug/Patent number(s):

- 14) Which of the following patent certifications does the application contain? (*Check all that apply and identify the patents to which each type of certification was made, as appropriate.*)

- No patent certifications are required (e.g., because application is based solely on published literature that does not cite a specific innovator product)
- 21 CFR 314.50(i)(1)(i)(A)(1): The patent information has not been submitted to FDA. (Paragraph I certification)
- 21 CFR 314.50(i)(1)(i)(A)(2): The patent has expired. (Paragraph II certification)

Patent number(s):

- 21 CFR 314.50(i)(1)(i)(A)(3): The date on which the patent will expire. (Paragraph III certification)

Patent number(s): 4814470*PED

Expiry date(s): 11/14/10

- 21 CFR 314.50(i)(1)(i)(A)(4): The patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the drug product for which the application is submitted. (Paragraph IV certification). *If Paragraph IV certification was submitted, proceed to question #15.*

- 21 CFR 314.50(i)(3): Statement that applicant has a licensing agreement with the NDA holder/patent owner (must also submit certification under 21 CFR 314.50(i)(1)(i)(A)(4) above). *If the applicant has a licensing agreement with the NDA holder/patent owner, proceed to question #15.*

- 21 CFR 314.50(i)(1)(ii): No relevant patents.

- 21 CFR 314.50(i)(1)(iii): The patent on the listed drug is a method of use patent

and the labeling for the drug product for which the applicant is seeking approval does not include any indications that are covered by the use patent as described in the corresponding use code in the Orange Book. Applicant must provide a statement that the method of use patent does not claim any of the proposed indications. (Section viii statement)

Patent number(s):

Method(s) of Use/Code(s):

15) Complete the following checklist **ONLY** for applications containing Paragraph IV certification and/or applications in which the applicant and patent holder have a licensing agreement:

(a) Patent number(s): 5698582 (7/3/12) 5698582*PED (1/3/13) 5714512 (7/3/12)
5714512*PED (1/3/13) 5750561 (7/3/12) 5750561*PED (1/3/13)
5438072 (11/22/13) 5438072*PED (5/22/14)

(b) Did the applicant submit a signed certification stating that the NDA holder and patent owner(s) were notified that this b(2) application was filed [21 CFR 314.52(b)]?
YES NO

(Submission dated 10/22/07)

If "NO", please contact the applicant and request the signed certification.

(c) Did the applicant submit documentation showing that the NDA holder and patent owner(s) received the notification [21 CFR 314.52(e)]? This is generally provided in the form of a registered mail receipt.
YES NO

(Submission dated 10/22/07)

If "NO", please contact the applicant and request the documentation.

(d) What is/are the date(s) on the registered mail receipt(s) (i.e., the date(s) the NDA holder and patent owner(s) received notification):

Date(s): 10/2/07 and 10/5/07

(e) Has the applicant been sued for patent infringement within 45-days of receipt of the notification listed above?

*Note that you may need to call the applicant (after 45 days of receipt of the notification) to verify this information **UNLESS** the applicant provided a written statement from the notified patent owner(s) that it consents to an immediate effective date of approval.*

YES NO Patent owner(s) consent(s) to an immediate effective date of approval

sanofi-aventis was sued over the '512 and '561 patents. The expiration date of the 30 month stay was 4/1/2010.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

FRANK H CROSS
03/07/2011

MEMORANDUM OF TELECON

DATE: November 23, 2010

TIME: 12:50 p.m.

APPLICATION NUMBER: NDA 022234, Docetaxel Injection, 20 mg/2 mL, 80 mg/8 mL and 160 mg/16 mL

BETWEEN:

Eric Floyd, Vice President – Global Regulatory Affairs
Laurie Wojtko, Sr. Associate – Global Regulatory Affairs
Wendy Tian, Associate Director – Global Regulatory Affairs
Lisa Zboril, Director Pharma Development – Global Regulatory Affairs
Ann Kamykowski, Sr. Label Editor
Kim Andersen, Label Editor
Tina Gonzales, Supervisor – Product Labeling
Ed Koo, Director – Preclinical Development
Andrew Knill, R&D Development Team Leader
Lorraine Webster, Manager – Preclinical Development
Mary Baker, Manager – Medical Affairs

Representing: HOSPIRA Inc.

Phone: 224-212-6158

AND

Anthony Murgo, M.D., M.S., FACP, Deputy Director, DDOP
Patricia Cortazar, M.D., Lead Medical Officer, DDOP
Kristen Snyder, M.D., Medical Officer, DDOP
Richard Lostritto, Ph.D., Director, ONDQA
Josephine Jee, Ph.D., Chemistry Reviewer, ONDQ
Leigh Verbois, Ph.D., Supervisory Pharmacologist, DDOP
Sachia Khasar, Ph.D., Pharmacology/Toxicology Reviewer, DDOP
Katherine Fedenko, M.S., C.R.N.P., Senior Clinical Analyst, DDOP
Susan Jenney, M.S., Safety Regulatory Project Manager, DDOP
Sara Simon, Regulatory Project Manager, OSE
Kristina Toliver, Director, OSE/DMEPA
Tamy Kim, PharmD., Associate Director of Regulatory Affairs, OODP
Frank Cross, Chief, Project Manager, Staff, DDOP
Modupe Fagbami, Regulatory Project Manager, DDOP

Representing: FDA

SUBJECT: Status of FDA Review of NDA 022234, Docetaxel Injection 20 mg/2 mL, 80 mg/8 mL and 160 mg/16 mL

The Agency informed the Applicant of the safety concern on both the carton and container labeling in their single vial 20 mg/ 2 mL given that there already exist a 2 vial formulation which needs no reconstitution. The Agency listed updating the labeling to ensure clarity and the Dear Healthcare Professional letter, as suggestions to solving this problem.

Hospira said that they had already anticipated the labeling issue and had recently revised their carton and container labeling and will send the revision to the Agency immediately after the meeting.

After a lengthy discussion on how to move forward with the submission, which is a conversion of Tentative Approval to Full Approval, the Applicant agreed to make the following updates to the labeling:

- Increase the Font Size of the strength
- Increase the Font size of the concentration and add a red band to the information for further highlight
- Add “Ready to add to Infusion Solution “ to Carton and Container
- Add a red band containing the Concentration “(10mg/mL)” to the Carton

Modupe Fagbami
RPM

Richard Lostritto, Ph.D., Meeting Chair
Division Director, ONDQA

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
03/07/2011

RICHARD T LOSTRITTO
03/07/2011

From: Fagbami, Modupe
Sent: Thursday, December 23, 2010 4:32 PM
To: 'Floyd, Eric'
Cc: Wojtko, Laurie M.; Cross Jr, Frank H
Subject: NDA 022243 Docetaxel Injection Hospira
Importance: High

Hi Eric,

Please find attached the FDA revisions to the Dear Health Care Professional Letter.

We will be sending the revised PI to you shortly.



22234 Dear Health
Care Profess...

Please let us know if you have any questions

Thank you.

Modupe O. Fagbami

RPM

Division of Drug Oncology Products

Office of Oncology Drug Products

CDER, FDA

10903 New Hampshire Avenue

WO-22, Room 2108

Silver Spring, Maryland 20993

Phone: 301-796-1348

Fax: 301-796-9845

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
02/24/2011

From: Fagbami, Modupe
Sent: Thursday, December 23, 2010 5:11 PM
To: 'Floyd, Eric'
Cc: Cross Jr, Frank H; Wojtko, Laurie M.
Subject: NDA 022243 Docetaxel Injection Hospira
Importance: High

Hi Eric,

As promised, please find the FDA revised PI

Please ensure that all the appropriate format changes are made



proposed-mulgrave
-redline of 1...

Kindly let me know if you have any questions

Thanks

Modupe O. Fagbami

RPM

Division of Drug Oncology Products

Office of Oncology Drug Products

CDER, FDA

10903 New Hampshire Avenue

WO-22, Room 2108

Silver Spring, Maryland 20993

Phone: 301-796-1348

Fax: 301-796-9845

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
02/24/2011

From: Fagbami, Modupe
Sent: Friday, January 28, 2011 10:44 AM
To: 'Wojtko, Laurie M.'
Cc: Cross Jr, Frank H; Fagbami, Modupe
Subject: RE: NDA 022234, Docetaxel - Labeling Status
Importance: High

Hi Laurie,

Right now the review team are working on your submission of January 27. I will get back to you if there is any further information needed.

Regarding our review timelines, those are internal information that we may not share, but I reassure you that we are actively working on making an action decision on this application and this will be communicated to you as soon as it is done.

Thank you.

Modupe Fagbami

From: Wojtko, Laurie M. [mailto:Laurie.Wojtko@hospira.com]
Sent: Friday, January 28, 2011 10:34 AM
To: Fagbami, Modupe
Subject: NDA 022234, Docetaxel - Labeling Status

Hi Modupe,

Thank you for confirming receipt of yesterday's labeling amendment. In follow-up, I'm hoping you can help me understand the progression of the labeling review. Can you tell me if all disciplines have now completed the review of the previous labeling amendment submitted on December 24? What is the estimated timeframe for the review of the amendment submitted yesterday? Thank you in advance for providing clarity on the process.

Kind regards,

Laurie Wojtko
Senior Associate
Global Regulatory Affairs
Hospira, Inc.
275 N. Field Dr.
Bldg. H2-2, Dept. 389
Lake Forest, IL 60045
P: 224-212-6158
F: 224-212-5401
www.hospira.com

CONFIDENTIALITY STATEMENT. This email and any attachment is for the sole use of the intended recipient and may contain private, confidential and/or privileged information that may be subject to Hospira internal policies. If you are not the intended recipient, any dissemination, distribution or copying is strictly prohibited. If you have received this transmission in error, please notify Hospira immediately by return email or by email to privacypostmaster@hospira.com and delete the message and all copies and attachments from your system.

Reference ID: 2910011

Reference ID: 2925482

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
02/24/2011

Reference ID: 2910011

Reference ID: 2925482

Cross Jr, Frank H

From: Cross Jr, Frank H
Sent: Friday, February 18, 2011 11:24 AM
To: Wojtko, Laurie M.
Subject: FDA Revised Labeling - NDA 022234, Docestatel

Importance: High

Attachments: proposed-redline (2).doc

Hello,

Please review the attached labeling and provide us with your feedback.

Thanks,
Frank (for Modupe)



proposed-redline
(2).doc (829 ...)

Frank H. Cross, Jr., MA, MT (ASCP)
Captain, USPHS Commissioned Corps
Chief, Project Management Staff
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research
US Food and Drug Administration
White Oak Bldg 22, Room 2110
10903 New Hampshire Avenue
Silver Spring, MD 20993
(301) 796-0876 (office)
(301) 796-9845 (fax)
frank.crossjr@fda.hhs.gov

45 Page(s) of Draft Labeling has been Withheld
in Full as B4 (CCI/TS) immediately following
this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

FRANK H CROSS

02/22/2011

Transmitted to Applicant on 2/18/11

REQUEST FOR DDMAC LABELING REVIEW CONSULTATION

****Please send immediately following the Filing/Planning meeting****

TO: **CDER-DDMAC-RPM: Salis, Olga**

FROM: (Name/Title, Office/Division/Phone number of requestor)
Modupe Fagbami/RPM/OODP/DDOP/301-796-1348

REQUEST DATE 2/9/2011	IND NO.	NDA. 022234	TYPE OF DOCUMENTS Conversion of TA to FA
--------------------------	---------	----------------	---

NAME OF DRUG Docetaxel	PRIORITY CONSIDERATION	CLASSIFICATION OF DRUG	DESIRED COMPLETION DATE (Generally 1 week before the wrap-up meeting) 2/11/2011
---------------------------	------------------------	------------------------	---

NAME OF FIRM:
Hospira

PDUFA Date: 3/23/2011. Action Expected ASAP

TYPE OF LABEL TO REVIEW

TYPE OF LABELING: (Check all that apply) <input checked="" type="checkbox"/> PACKAGE INSERT (PI) <input checked="" type="checkbox"/> PATIENT PACKAGE INSERT (PPI) <input checked="" type="checkbox"/> CARTON/CONTAINER LABELING <input type="checkbox"/> MEDICATION GUIDE <input type="checkbox"/> INSTRUCTIONS FOR USE (IFU)	TYPE OF APPLICATION/SUBMISSION <input type="checkbox"/> ORIGINAL NDA/BLA <input type="checkbox"/> IND <input type="checkbox"/> EFFICACY SUPPLEMENT <input type="checkbox"/> SAFETY SUPPLEMENT <input type="checkbox"/> LABELING SUPPLEMENT <input type="checkbox"/> PLR CONVERSION	REASON FOR LABELING CONSULT <input type="checkbox"/> INITIAL PROPOSED LABELING <input type="checkbox"/> LABELING REVISION
--	---	--

EDR link to submission:
Original Submission

[<\\FDSWA150\NONECTD\N22234\N_0to_00\2010-09-23>](mailto:FDSWA150\NONECTD\N22234\N_0to_00\2010-09-23)

Please Note: There is no need to send labeling at this time. DDMAC reviews substantially complete labeling, which has already been marked up by the CDER Review Team. After the disciplines have completed their sections of the labeling, a full review team labeling meeting can be held to go over all of the revisions. Within a week after this meeting, "substantially complete" labeling should be sent to DDMAC. Once the substantially complete labeling is received, DDMAC will complete its review within 14 calendar days.

COMMENTS/SPECIAL INSTRUCTIONS:
MO: Kristen Snyder

Please find EDR location of the Applicant's final PI and labeling.

EDR Location: [\\FDSWA150\NONECTD\4442445](mailto:FDSWA150\NONECTD\4442445)

SIGNATURE OF REQUESTER: Modupe Fagbami

SIGNATURE OF RECEIVER Reference ID: 2903255	METHOD OF DELIVERY (Check one) <input checked="" type="checkbox"/> eMAIL <input type="checkbox"/> HAND
---	--

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
02/09/2011

From: Fagbami, Modupe
Sent: Monday, January 24, 2011 4:48 PM
To: 'Wojtko, Laurie M.'
Subject: NDA 022234 Docetaxel FDA Information Request
Importance: High

Dear Ms. Wojtko,

Please find attached the FDA revisions to your proposed PI of 12-24-2010 for your response on or before Thursday, January 27, 2011.



proposed-redline PI
of 1-11-11...

Kindly let me know if you have any questions

Thank you

Modupe O. Fagbami

RPM

Division of Drug Oncology Products

Office of Oncology Drug Products

CDER, FDA

10903 New Hampshire Avenue

WO-22, Room 2108

Silver Spring, Maryland 20993

Phone: 301-796-1348

Fax: 301-796-9845

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
01/24/2011

From: Fagbami, Modupe
Sent: Monday, January 24, 2011 4:38 PM
To: 'Wojtko, Laurie M.'
Subject: NDA 022234 Docetaxel FDA Information Request
Importance: High

Dear Ms. Wojtko,

Please find the following FDA Information request for your response on or before Thursday, January 27, 2011.

1. Utilize one uniform set of carton and container labels for drug products manufactured by either Hospira Australia Pty Ltd, Mulgrave, Australia or by Zydus Hospira Oncology Private Ltd., Gujara, India. The only site-specific difference in these labels should be the different manufacturing sites and their addresses.
2. Replace [REDACTED] (b) (4) with "Manufactured by: Hospira Australia Pty Ltd., Mulgrave, Australia. Distributed by: Hospira Inc., Lake Forest, IL 60045, USA" and [REDACTED] (b) (4) with "Manufactured by: Zydus Hospira Oncology Private Ltd., Gujara, India. Distributed by: Hospira Inc., Lake Forest, IL 60054, USA". Apply this revision to all carton and container labels.

Kindly let me know if you have any questions.

Thank you.

Modupe O. Fagbami

RPM

Division of Drug Oncology Products

Office of Oncology Drug Products

CDER, FDA

10903 New Hampshire Avenue

WO-22, Room 2108

Silver Spring, Maryland 20993

Phone: 301-796-1348

Fax: 301-796-9845

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
01/24/2011

Fagbami, Modupe

From: Fagbami, Modupe
ent: Thursday, December 23, 2010 4:32 PM
fo: 'Floyd, Eric'
Cc: Wojtko, Laurie M.; Cross Jr, Frank H
Subject: NDA 022243 Docetaxel Injection Hospira

Importance: High

Attachments: 22234 Dear Health Care Professional_redline 12 23 2010.doc

Hi Eric,

Please find attached the FDA revisions to the Dear Health Care Professional Letter.

We will be sending the revised PI to you shortly.



22234 Dear Health
Care Profess...

Please let us know if you have any questions

Thank you.

Modupe O. Fagbami

.PM

Division of Drug Oncology Products

Office of Oncology Drug Products

CDER, FDA

10903 New Hampshire Avenue

WO-22, Room 2108

Silver Spring, Maryland 20993

Phone: 301-796-1348

Fax: 301-796-9845



Important Preparation Information For Docetaxel Injection

Dear Health Care Professional,

Hospira, Inc. is writing to inform you that the product concentration and preparation procedures for Hospira's Docetaxel Injection is different than those required for other marketed Docetaxel Injection products. This important information can help avoid errors when compounding Docetaxel Injection made by Hospira and other manufacturers.

Hospira's Docetaxel Injection is a formulation that may be directly injected into the infusion container without an intermediate dilution step. This differs from the Taxotere[®] 2-vial product and other Docetaxel products, which are concentrated formulations, require mixing with a special diluent before injection into the infusion container.

Hospira's Docetaxel Injection is available in a 10 mg/mL concentration and the following strengths: 20 mg/2 mL, 80 mg/8 mL and 160 mg/16 mL. This 10 mg/mL concentration also differs from the Taxotere[®] 1-vial product which is a 20 mg/mL concentration. Therefore, it is important to check the concentration and follow the preparation instructions carefully before using Docetaxel products.

Follow the Hospira Docetaxel Injection drug preparation instructions as described under the product Full Prescribing Information:

- Aseptically withdraw the required amount of Docetaxel Injection (10 mg docetaxel/mL) with a calibrated syringe and inject into a 250 mL infusion bag or bottle of either 0.9% Sodium Chloride solution or 5% Dextrose solution to produce a final concentration of 0.3 mg/mL to 0.74 mg/mL.
If a dose greater than 200 mg of docetaxel is required, use a larger volume of the infusion vehicle so that a concentration of 0.74 mg/mL docetaxel is not exceeded.
- Thoroughly mix the infusion by gentle manual rotation.
- As with all parenteral products, Docetaxel Injection should be inspected visually for particulate matter or discoloration prior to administration whenever the solution and container permit. If the Docetaxel Injection or diluted solution for intravenous infusion is not clear or appears to have precipitation, it should be discarded.



Please consult the current prescribing information for Docetaxel Injection. If you need further information related to this product, please contact Medical Communications at medcom@hospira.com or 1-800-615-0187.

Cross Jr, Frank H

From: Cross Jr, Frank H
Sent: Wednesday, December 22, 2010 5:08 PM
To: 'Wojtko, Laurie M.'
Cc: Tian, Wendy W.; 'eric.floyd@hospira.com'; Fagbami, Modupe
Subject: NDA 022234, Docetaxel - Labeling Comments
Importance: High
Attachments: 22234 PI carton and container labeling comments.doc

Dear Ms. Wojtko,

Attached are our comments regarding your proposed labeling for this product.

Please provide a response to the attached document.

Sincerely,
Frank Cross (for Ms. Modupe Fagbami, RPM)

Frank H. Cross, Jr., MA, MT (ASCP)
Captain, USPHS Commissioned Corps
Chief, Project Management Staff
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research
US Food and Drug Administration
White Oak Bldg 22, Room 2110
10903 New Hampshire Avenue
Silver Spring, MD 20993
(301) 796-0876 (office)
(301) 796-9845 (fax)
frank.crossjr@fda.hhs.gov

1. Package Insert Labeling:
 - a) Delete the abbreviation “IV” found in several areas of the Highlights of Prescribing Information section and in the Patient Information section of the insert. Replace the abbreviation “BID” (found in section 2.6 Premedication Regimen) with the text “twice daily”
 - b) The terms (b) (4) and (b) (4) are used throughout the insert to describe the 20 mg/2 mL vial and (80 mg/8 mL and 160 mg/16 mL) vials, respectively. Replace the text (b) (4) with “single use vial” and the text (b) (4) with “multi-use vial”.
2. Carton/Container Labeling:
 - a) General Comment:

The abbreviation “IV” is used on the principal display panel in the route of administration and on the side panel on the carton in the Directions for Use. As part of a national campaign to decrease the use of dangerous abbreviations, the FDA agreed to not use such abbreviations in the approved labeling of products. Therefore, we recommend “IV” be replaced with the text “Intravenous”.
 - b) Container Labels:
 1. The concentration of this product differs from the currently approved Taxotere 1-vial product. In order to highlight this difference, place and box the following statement prominently on the principal display panel below the route of administration, “Ready to add to infusion solution. Check concentration prior to preparation. See package insert for complete instructions”.
 2. Expand the color block (which encloses the established name) to include the total drug content statement.
 3. In order to make room on the 20 mg/2 mL label for the information requested in B-1 above, we recommend deleting the (b) (4) and (b) (4) statements. Additionally, relocate the “Caution: Cytotoxic agent” statement to the side panel.
 4. Consider using a different orientation for the layout of the information on the principal display panel in order to accommodate the above recommended revisions to the container labels.
 - c) Carton Labeling:
 1. Add a banner to the principal display panel with the following statement: “New concentration and preparation”. Please note this statement must be removed after six months.
 2. The 20 mg and 160 mg strengths are both presented in (b) (4) color blocks that don’t make the total drug content stand out. Ensure these strengths are well differentiated from one another and from the 80 mg strength.

3. The red color block at the top portion of the carton labeling contains the drug concentration “10 mg/mL”. Practitioners may misinterpret this statement as the total drug content, especially on the 20 mg/2 mL strength. Therefore, we recommend you also include the total drug content in the color block [e.g., 20 mg/2 mL (10 mg/mL), 80 mg/8 mL (10 mg/mL), or 160 mg/16 mL (10 mg/mL)], as appropriate.
4. The top portion of the label (above the established name) appears cluttered. Delete the statement [REDACTED] and relocate the “Rx only” statement to one of the side panels.
5. Expand the color block (which encloses the established name) to include the total drug content statement.
6. Increase the size of the statement “Ready to add to infusion solution” on the principal display panel in order to make it more prominent.
7. Relocate the statement “Warning: Keep out of reach of children” to one of the side panels. In the position where the warning statement is currently located, place the statement “Caution: Cytotoxic Agent” and use a black font color.
8. The statement “Caution: Cytotoxic Agent” is in the red color block at the bottom portion of the carton labeling. Delete this statement from this area and relocate it as described in comment C-7, above. Place the following statement in the red color block at the bottom of the carton labeling: “Check concentration prior to preparation. See package insert for complete instructions”.
9. Delete the section [REDACTED] from the side panel. The instructions in that section are not complete so we prefer healthcare practitioners read the insert for full directions for use.
10. Under the section [REDACTED] delete the first sentence (the sentence begins with the words [REDACTED]). Additionally, change the [REDACTED] heading to “Usual Dosage” since the actual dosage and administration instructions are not provided here.

2 Page(s) has been Withheld in Full as B4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

FRANK H CROSS
12/22/2010

From: Fagbami, Modupe
Sent: Monday, November 29, 2010 5:43 PM
To: 'Wojtko, Laurie M.'
Cc: Tian, Wendy W.; Cross Jr, Frank H
Subject: NDA 022234 Docetaxel Injection Hospira FDA Revisions to PI and The Dear Health Care Professional
Importance: High

Hi Laurie,

Please find attached the FDA revisions to your Dear Health Care Professional Letter of September 23, 2010, and your PI that was submitted on November 9, 2010.



Docetaxel Injection
NDA 022234...



FDA Revision to
Hospira Redlin...

We also have the following comments for the PI. Kindly send your response to the Agency on or before 5:00 pm, EST Friday, December 3, 2010.

DMEPA:

1. Delete the abbreviation "IV" found in several areas of the Highlights of Prescribing Information section and in the Patient Information section of the insert. Replace the abbreviation "BID" (found in section 2.6 Premedication Regimen) with the text "twice daily"

2. The term (b) (4) is used throughout the insert to describe the 20 mg/2 mL vial. Replace the text (b) (4) with "single use vial".

FORMATTING:

Correct all formatting and spelling errors through out the PI

Kindly let me know if you have any questions.

Thank you

Modupe O. Fagbami

RPM

Division of Drug Oncology Products

Office of Oncology Drug Products

CDER, FDA

10903 New Hampshire Avenue


WO-22, Room 2108

Silver Spring, Maryland 20993

Phone: 301-796-1348

Fax: 301-796-9845

APPEARS THIS WAY ON ORIGINAL



This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
11/29/2010

MEMORANDUM OF TELECON

DATE: November 23, 2010

TIME: 12:50 p.m.

APPLICATION NUMBER: NDA 022234, Docetaxel Injection, 20 mg/2 mL, 80 mg/8 mL and 160 mg/16 mL

BETWEEN:

Eric Floyd, Vice President – Global Regulatory Affairs
Laurie Wojtko, Sr. Associate – Global Regulatory Affairs
Wendy Tian, Associate Director – Global Regulatory Affairs
Lisa Zboril, Director Pharma Development – Global Regulatory Affairs
Ann Kamykowski, Sr. Label Editor
Kim Andersen, Label Editor
Tina Gonzales, Supervisor – Product Labeling
Ed Koo, Director – Preclinical Development
Andrew Knill, R&D Development Team Leader
Lorraine Webster, Manager – Preclinical Development
Mary Baker, Manager – Medical Affairs

Representing: HOSPIRA Inc.

Phone: 224-212-6158

AND

Anthony Murgo, M.D., M.S., FACP, Deputy Director, DDOP
Patricia Cortazar, M.D., Lead Medical Officer, DDOP
Kristen Snyder, M.D., Medical Officer, DDOP
Richard Lostritto, Ph.D., Director, ONDQA
Josephine Jee, Ph.D., Chemistry Reviewer, ONDQ
Leigh Verbois, Ph.D., Supervisory Pharmacologist, DDOP
Sachia Khasar, Ph.D., Pharmacology/Toxicology Reviewer, DDOP
Katherine Fedenko, M.S., C.R.N.P., Senior Clinical Analyst, DDOP
Susan Jenney, M.S., Safety Regulatory Project Manager, DDOP
Sara Simon, Regulatory Project Manager, OSE
Kristina Toliver, Director, OSE/DMEPA
Tamy Kim, PharmD., Associate Director of Regulatory Affairs, OODP
Frank Cross, Chief, Project Manager, Staff, DDOP
Modupe Fagbami, Regulatory Project Manager, DDOP

Representing: FDA

SUBJECT: Status of FDA Review of NDA 022234, Docetaxel Injection 20 mg/2 mL, 80 mg/8 mL and 160 mg/16 mL

The Agency informed the Applicant of the safety concern on both the carton and container labeling in their single vial 20 mg/ 2 mL given that there already exist a 2 vial formulation which needs no reconstitution. The Agency listed updating the labeling to ensure clarity and the Dear Healthcare Professional letter, as suggestions to solving this problem.

Hospira said that they had already anticipated the labeling issue and had recently revised their carton and container labeling and will send the revision to the Agency immediately after the meeting.

After a lengthy discussion on how to move forward with the submission, which is a conversion of Tentative Approval to Full Approval, the Applicant agreed to make the following updates to the labeling:

- Increase the Font Size of the strength
- Increase the Font size of the concentration and add a red band to the information for further highlight
- Add “Ready to add to Infusion Solution “ to Carton and Container
- Add a red band containing the Concentration “(10mg/mL)” to the Carton

Modupe Fagbami
RPM

Richard Lostritto, Ph.D., Meeting Chair
Division Director, ONDQA

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
03/07/2011

RICHARD T LOSTRITTO
03/07/2011

MEMORANDUM OF TELECON

DATE: November 18, 2010

TIME: 12:15 p.m.

APPLICATION NUMBER: NDA 022234, Docetaxel Injection, 20 mg/2 mL, 80 mg/8 mL and
160 mg/16 mL

BETWEEN:

Eric Floyd, Vice President, Global Regulatory Affairs
Lisa Zboril, Director Global Pharma Development, Global Regulatory Affairs
Laurie Wojtko, Sr. Associate, Global Regulatory Affairs
Wendy Tian, Associate Director, Global Regulatory Affairs

Representing: HOSPIRA Inc.

Phone: 224-212-6158

AND

Name: Frank H. Cross Jr. Chief, Project Management, Staff, DDOP, HFD 150
Modupe Fagbami, Project Manager, DDOP, HFD 150

SUBJECT: Conveyance of Team's Review Status of NDA 022234, Docetaxel Injection, to
the Applicant and Request for Teleconference.

Agency:

The Agency informed the Applicant that the Agency will not be able to send the revised Package Insert, Carton and Container labeling as previously discussed on November 18, 2010.

The Agency requested a teleconference with the Applicant on November 23, 2010 between 12:30 pm and 12:45 pm to facilitate the Applicant's responses to the labeling comments that will be sent to the Applicant after the teleconference.

Applicant:

The Applicant asked for specific details of the teleconference discussion.

Agency:

The Agency was unable to provide the specifics since reviews are not yet completed. The Agency requested the Applicant to send the call-in phone information for the proposed teleconference to the Regulatory Project Manager.

Modupe Fagbami,
Regulatory Project Manager

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
11/22/2010



November 3, 2010

Dr. Robert Justice, M.D., M.S.
Director, Division of Drug Oncology Products
Center for Drug Evaluation and Research
Food and Drug Administration
Central Document Room (CDR)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Cc: Frank Cross
Modupe Fagbami

Re: NDA 22-234, Docetaxel Injection, 20 mg/2 mL, 80 mg/8 mL and 160 mg/16 mL

(b) (4)
**FROM SEPTEMBER 23,
2010 AMENDMENT**

Further to your conversation with Eric Floyd of Hospira this afternoon, Hospira hereby
(b) (4)
from the Request for Full Approval amendment
submitted on September 23, 2010. The only item remaining in the amendment is updated
Hospira labeling to comply with the latest revision of the reference listed drug labeling.

For electronic signatures a letter on non-repudiation for Laurie Wojtko is on file with the
FDA.

The files have been scanned for viruses using the current version of McAfee VirusScan
Enterprise 8.5.0 virus scanning software.

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60064



We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

Laurie Wojtko 11-3-10

Laurie Wojtko
Sr. Associate, Global Regulatory Affairs
Hospira, Inc.
Phone: 224-212-6158
Fax: 224-212-5401
E-mail: laurie.wojtko@hospira.com

99 Page(s) of Draft Labeling has been
Withheld in Full as B4 (CCI/TS) immediately
following this page

REQUEST FOR CONSULTATION

TO (Division/Office):

Mail: OSE/Sarah Simon

FROM: **DDOP/Modupe Fagbami/RPM/301-796-1348**

DATE: 11/2/2010	IND NO.	NDA NO. 022234	TYPE OF DOCUMENT: NDA Re-Submission after a Tentative Approval for a conversion to Full Approval	DATE OF DOCUMENT: 9/23/2010
NAME OF DRUG: Docetaxel Injection 20 mg/2 mL single dose vial, 80 mg/8 mL multi-dose vial and 160 mg/16 mL multi-dose vial		PRIORITY CONSIDERATION	CLASSIFICATION OF DRUG: 5	DESIRED COMPLETION DATE Label Review dates to be scheduled.

NAME OF FIRM: Hospira

REASON FOR REQUEST

I. GENERAL

- | | | |
|--|--|--|
| <input type="checkbox"/> NEW PROTOCOL | <input type="checkbox"/> PRE--NDA MEETING | <input type="checkbox"/> RESPONSE TO DEFICIENCY LETTER |
| <input type="checkbox"/> PROGRESS REPORT | <input type="checkbox"/> END OF PHASE II MEETING | <input type="checkbox"/> FINAL PRINTED LABELING |
| <input type="checkbox"/> NEW CORRESPONDENCE | <input checked="" type="checkbox"/> RESUBMISSION | <input type="checkbox"/> LABELING REVISION |
| <input type="checkbox"/> DRUG ADVERTISING | <input type="checkbox"/> SAFETY/EFFICACY | <input type="checkbox"/> ORIGINAL NEW CORRESPONDENCE |
| <input type="checkbox"/> ADVERSE REACTION REPORT | <input type="checkbox"/> PAPER NDA | <input type="checkbox"/> FORMULATIVE REVIEW |
| <input type="checkbox"/> MANUFACTURING CHANGE/ADDITION | <input type="checkbox"/> CONTROL SUPPLEMENT | <input type="checkbox"/> OTHER (SPECIFY BELOW): |
| <input type="checkbox"/> MEETING PLANNED BY | | |

II. BIOMETRICS

STATISTICAL EVALUATION BRANCH	STATISTICAL APPLICATION BRANCH
<input type="checkbox"/> TYPE A OR B NDA REVIEW <input type="checkbox"/> END OF PHASE II MEETING <input type="checkbox"/> CONTROLLED STUDIES <input type="checkbox"/> PROTOCOL REVIEW <input type="checkbox"/> OTHER (SPECIFY BELOW):	<input type="checkbox"/> CHEMISTRY REVIEW <input type="checkbox"/> PHARMACOLOGY <input type="checkbox"/> BIOPHARMACEUTICS <input type="checkbox"/> OTHER (SPECIFY BELOW):

III. BIOPHARMACEUTICS

- | | |
|--|---|
| <input type="checkbox"/> DISSOLUTION | <input type="checkbox"/> DEFICIENCY LETTER RESPONSE |
| <input type="checkbox"/> BIOAVAILABILITY STUDIES | <input type="checkbox"/> PROTOCOL-BIOPHARMACEUTICS |
| <input type="checkbox"/> PHASE IV STUDIES | <input type="checkbox"/> IN-VIVO WAIVER REQUEST |

IV. DRUG EXPERIENCE

- | | |
|--|--|
| <input type="checkbox"/> PHASE IV SURVEILLANCE/EPIDEMIOLOGY PROTOCOL | <input type="checkbox"/> REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY |
| <input type="checkbox"/> DRUG USE e.g. POPULATION EXPOSURE, ASSOCIATED DIAGNOSES | <input type="checkbox"/> SUMMARY OF ADVERSE EXPERIENCE |
| <input type="checkbox"/> CASE REPORTS OF SPECIFIC REACTIONS (List below) | <input type="checkbox"/> POISON RISK ANALYSIS |
| <input type="checkbox"/> COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP | |

V. SCIENTIFIC INVESTIGATIONS

CLINICAL

PRECLINICAL

COMMENTS/SPECIAL INSTRUCTIONS:

Please review the attached submission for this 505b2 label for medication errors. It is due March 23, 2011 (Target Date is 1/28/2011) but we are requesting you provide us with your consult by February 1, 2011. Thank you.

In addition, DDOP is requesting for Loretta Holmes the DMEPA reviewer who reviewed our other Docetaxels as the reviewer for this submission

Please find the link to the submission: \\FDSWA150\NONECTD\N22234\N_000\2010-09-23

MO: Kristen Snyder

SIGNATURE OF REQUESTER: Modupe Fagbami -RPM	METHOD OF DELIVERY (Check one) <input type="checkbox"/> E-MAIL and DARRTS <input type="checkbox"/> HAND
SIGNATURE OF RECEIVER	SIGNATURE OF DELIVERER

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
11/02/2010



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 022234

ACKNOWLEDGE CLASS 2 RESPONSE

Hospira, Inc.
Attention: Laurie Wojtko
Senior Associate, Global Regulatory Affairs
275 North Field Drive Dept. 389, Bldg. H2-2
Lake Forest, IL 60064

Dear Ms. Wojtko:

We acknowledge receipt on September 23, 2010, of your September 23, 2010, resubmission to your new drug application for Docetaxel Injection, 20 mg/2 mL single dose vial, 80 mg/8 mL multi-dose vial and 160 mg/16 mL multi-dose vial requesting full approval in response to our tentative approval letters.

We consider this a complete, Class 2 response to our August 11, 2008 and December 11, 2009, action letters. Therefore, the user fee goal date is March 23, 2011.

If you have any questions, call me at (301) 796-1348.

Sincerely,

{See appended electronic signature page}

Modupe Fagbami
Regulatory Project Manager
Division of Drug Oncology Products
Office of Oncology Products
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MODUPE O FAGBAMI
11/01/2010

CMC MICRO & STERILITY ASSURANCE
REVIEW REQUEST

TO (Division/Office): **New Drug Microbiology Staff**
David Hussong/Jim McVey/Sylvia Gantt

E-mail to: CDER OPS IO MICRO
Paper mail to: WO Bldg 51, Room 4193

FROM: Deborah Mesmer, ONDQA PM, 301.796.4023

PROJECT MANAGER (if other than sender):

REQUEST DATE 10/4/10	IND NO.	NDA NO. 22234/000	TYPE OF DOCUMENT 22234/000	DATE OF DOCUMENT September 23, 2010
-------------------------	---------	----------------------	-------------------------------	--

NAMES OF DRUG Docetaxel Injection, 20 mg/2 mL, 80 mg/8 mL and 160 mg/16 mL	PRIORITY CONSIDERATION	PDUFA DATE Resubmission class (I or II) not determined yet. Clinical team meeting 9.29. 10	DESIRED COMPLETION DATE PDUFA 2 moths or 6 months from date of document
---	------------------------	---	--

NAME OF APPLICANT OR SPONSOR: **Hospira, Inc**

GENERAL PROVISIONS IN APPLICATION

- | | |
|---|---|
| <input type="checkbox"/> 30-DAY SAFETY REVIEW NEEDED | <input type="checkbox"/> CBE-0 SUPPLEMENT |
| <input type="checkbox"/> NDA FILING REVIEW NEEDED BY: _____ | <input type="checkbox"/> CBE-30 SUPPLEMENT |
| <input type="checkbox"/> BUNDLED | <input type="checkbox"/> CHANGE IN DOSAGE, STRENGTH / POTENCY |
| <input type="checkbox"/> DOCUMENT IN EDR | |

COMMENTS / SPECIAL INSTRUCTIONS:

Requesting microbiology review for supplement that provides for: NDA 22234/000. (b) (4)

Clinical team meeting October 29, 2010 1:00 p.m.

Link to electronic submission \\fdswa150\NONECTD\N22234\N_000\2010-09-23

Chemistry reviewer: Josephine Jee
Project Manager for Quality: Debbie Mesmer
OND Project Manager: Modupe Fagbami

Please advise Debbie Mesmer of assigned reviewer

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DEBORAH M MESMER
10/14/2010



September 23, 2010

Dr. Robert Justice
Director, Division of Drug Oncology Products
Center for Drug Evaluation and Research
Food and Drug Administration
Central Document Room (CDR)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Re: NDA 22-234, Docetaxel Injection, 20 mg/2 mL, 80 mg/8 mL and 160 mg/16 mL

MINOR AMENDMENT – FULL APPROVAL REQUESTED

Hospira, Inc. hereby submits a minor amendment to the above-referenced new drug application for Docetaxel Injection, 20 mg/2 mL single dose vial, 80 mg/8 mL multi-dose vial and 160 mg/16 mL multi-dose vial. This is in response to the Agency's tentative approval letters dated August 11, 2008 and December 11, 2009. For ease of review, copies of these correspondences are included herein.

We note and acknowledge that the reference listed drug (RLD), Taxotere Injection of Sanofi-Aventis, is subject to a period of patent protection, U.S. Patent No 4,814,470, 5,438,072, 5,698,582, 5,714,512 B1 and 5,750,561 B1. We acknowledge that the above referenced NDA was filed with a Paragraph III certification for Patent No 4,814,470 and Paragraph IV certifications for the remaining patents. Sanofi-Aventis has only challenged Hospira's Paragraph IV certification on patents 5,714,512 B1 and 5,750,561 B1. Hospira asserts that the expiration of the 30-month period provided for in Section 505(c)(3)(C) occurred on April 1, 2010 as Sanofi-Aventis received notification on March 30, 2007. Additionally, per e-mail correspondence from Ms. Modupe Fagbami on January 20, 2010, our application will be eligible for final approval as soon as May 14, 2010, upon expiry of the patent 4,814,470. Due to the granting of pediatric exclusivity, this date has been extended by 6 months to November 14, 2010. Based upon this information, Hospira hereby requests full approval of this NDA.

The changes made to the application since the product was tentatively approved are explained in the attached Summary of Change document. Hospira has provided copies of proposed labeling that will be used in manufacturing product at the Mulgrave, Australia facility and Zydus Hospira Oncology Private Ltd. (ZHOPL), India facility. Per FDA's request a copy of the Dear Health Care Professional letter that will be submitted to MedWatch upon approval has been provided.

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60064



For electronic signatures a letter on non-repudiation for Laurie Wojtko is on file with the FDA.

The files have been scanned for viruses using the current version of McAfee VirusScan Enterprise 8.5.0 virus scanning software.

We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

Laurie Wojtko 9-23-2010

Laurie Wojtko
Sr. Associate, Global Regulatory Affairs
Hospira, Inc.
Phone: 224-212-6158
Fax: 224-212-5401
E-mail: laurie.wojtko@hospira.com

REQUEST FOR CONSULTATION

TO (Office/Division): David Hussong/Jim McVey/Sylvia Gantt
NEW DRUG MICROBIOLOGY STAFF
OC/OO/CDER/OPS/NDMS - HFD-805

FROM (Name, Office/Division, and Phone Number of Requestor): Terrance
Ocheltree through Debbie Mesmer, Office of New Drug
Quality Assessment, 301 796-4023

DATE
November 23, 2009

IND NO.

NDA NO.
22-234

TYPE OF DOCUMENT
amendment- class 2
resubmission to
tentatively approved NDA

DATE OF DOCUMENT
June 12, 2009

NAME OF DRUG
Docetaxel injection

PRIORITY CONSIDERATION
Class 2 resubmission

CLASSIFICATION OF DRUG

DESIRED COMPLETION DATE
PDUFA date: December
12, 2009

NAME OF FIRM: Hospira

REASON FOR REQUEST

I. GENERAL

- | | | |
|--|--|--|
| <input type="checkbox"/> NEW PROTOCOL | <input type="checkbox"/> PRE-NDA MEETING | <input type="checkbox"/> RESPONSE TO DEFICIENCY LETTER |
| <input type="checkbox"/> PROGRESS REPORT | <input type="checkbox"/> END-OF-PHASE 2a MEETING | <input type="checkbox"/> FINAL PRINTED LABELING |
| <input type="checkbox"/> NEW CORRESPONDENCE | <input type="checkbox"/> END-OF-PHASE 2 MEETING | <input type="checkbox"/> LABELING REVISION |
| <input type="checkbox"/> DRUG ADVERTISING | <input checked="" type="checkbox"/> RESUBMISSION | <input type="checkbox"/> ORIGINAL NEW CORRESPONDENCE |
| <input type="checkbox"/> ADVERSE REACTION REPORT | <input type="checkbox"/> SAFETY / EFFICACY | <input type="checkbox"/> FORMULATIVE REVIEW |
| <input type="checkbox"/> MANUFACTURING CHANGE / ADDITION | <input type="checkbox"/> PAPER NDA | <input type="checkbox"/> OTHER (SPECIFY BELOW): |
| <input type="checkbox"/> MEETING PLANNED BY | <input type="checkbox"/> CONTROL SUPPLEMENT | |

II. BIOMETRICS

- | | |
|---|---|
| <input type="checkbox"/> PRIORITY P NDA REVIEW | <input type="checkbox"/> CHEMISTRY REVIEW |
| <input type="checkbox"/> END-OF-PHASE 2 MEETING | <input type="checkbox"/> PHARMACOLOGY |
| <input type="checkbox"/> CONTROLLED STUDIES | <input type="checkbox"/> BIOPHARMACEUTICS |
| <input type="checkbox"/> PROTOCOL REVIEW | <input type="checkbox"/> OTHER (SPECIFY BELOW): |
| <input type="checkbox"/> OTHER (SPECIFY BELOW): | |

III. BIOPHARMACEUTICS

- | | |
|--|--|
| <input type="checkbox"/> DISSOLUTION | <input type="checkbox"/> DEFICIENCY LETTER RESPONSE |
| <input type="checkbox"/> BIOAVAILABILITY STUDIES | <input type="checkbox"/> PROTOCOL - BIOPHARMACEUTICS |
| <input type="checkbox"/> PHASE 4 STUDIES | <input type="checkbox"/> IN-VIVO WAIVER REQUEST |

IV. DRUG SAFETY

- | | |
|--|--|
| <input type="checkbox"/> PHASE 4 SURVEILLANCE/EPIDEMIOLOGY PROTOCOL | <input type="checkbox"/> REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY |
| <input type="checkbox"/> DRUG USE, e.g., POPULATION EXPOSURE, ASSOCIATED DIAGNOSES | <input type="checkbox"/> SUMMARY OF ADVERSE EXPERIENCE |
| <input type="checkbox"/> CASE REPORTS OF SPECIFIC REACTIONS (List below) | <input type="checkbox"/> POISON RISK ANALYSIS |
| <input type="checkbox"/> COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP | |

V. SCIENTIFIC INVESTIGATIONS

- | | |
|-----------------------------------|--------------------------------------|
| <input type="checkbox"/> CLINICAL | <input type="checkbox"/> NONCLINICAL |
|-----------------------------------|--------------------------------------|

COMMENTS / SPECIAL INSTRUCTIONS: ONDQA/DDOP is requesting to have a microbiology review of Hospira's amendment/class 2 resubmission of June 12, 2009, for the tentatively approved NDA 22-324 for Docetaxel injection. This amendment provides for a new site for DP manufacturing, ZHOPL, located in India. Specifically, the ZHPOL site is using (b)(4) stoppers. Please review the sterilization process at ZHOPL and the (b)(4) stoppers and provide your input. The applicant has provided their sterilization process validation. (The last micro review for the application was by Anastacia Lolas dated June 9, 2008.) Please accept Debbie Mesmer's personal apologies for the tardiness of this request, as the PDUFA goal date for this submission is December 12, 2009. Please contact Debbie with any problems regarding access of materials, 301-796-4023. Please contact Josephine Jee regarding questions with the application, 301-796-1375

Link to amendment: \\Fds\swa150\nonectd\4150014

Josephine Jee--CMC reviewer
Qin Ryan-- Clinical reviewer
OND Project Manager-- Madupe Fagbami
Quality Project Manager- -Debbie Mesmer

SIGNATURE OF REQUESTOR

{See appended electronic signature page}

METHOD OF DELIVERY (Check one)

DFS EMAIL MAIL HAND

PRINTED NAME AND SIGNATURE OF RECEIVER

PRINTED NAME AND SIGNATURE OF DELIVERER

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22234	ORIG-1	HOSPIRA INC	DOCETAXEL INJECTION

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DEBORAH M MESMER
11/23/2009

TERRANCE W OCHELTRREE
11/23/2009



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville, MD 20857

NDA 22-234

Hospira, Inc.
Attention: Judith Zutkis
Director, Global Regulatory Affairs
275 N. Field Drive
D-0389, Bldg H2-2N
Lake Forest, IL 60045-5046

Dear Ms. Zutkis:

Please refer to your new drug application dated July 9, 2007, received July 11, 2007, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Docetaxel Injection, 20 mg/2 mL single-dose vial, 80 mg/8 mL multi-dose vial, 160 mg/16 mL multi-dose vial.

Please also refer to your submission dated April 24, 2008, received April 28, 2008, which extended the due date for this application to August 11, 2008.

We acknowledge receipt of your submissions dated September 14, 27, October 22, November 15, and 20 (2), 2007; March 14, April 24 (2), May 8, July 30 (2), August 8 (two electronic submissions), and 11 (electronic), 2008.

This NDA provides for the use of Docetaxel Injection, 20 mg/2 mL single-dose vial, 80 mg/8 mL multi-dose vial, and 160 mg/16 mL multi-dose vial for locally advanced or metastatic breast cancer after failure of prior chemotherapy, in combination with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive breast cancer, locally advanced or metastatic non-small lung cancer after failure of prior platinum-based chemotherapy, in combination with cisplatin for unresectable, locally advanced or metastatic untreated non-small cell lung cancer, in combination with prednisone for androgen independent (hormone refractory) metastatic prostate cancer.

We completed our review of this application, as amended. It is tentatively approved under 21 CFR 314.105 for use as recommended in the agreed upon labeling (refer to the enclosed text for the package insert, enclosed text for the patient package insert, enclosed immediate container and carton labels). This determination is contingent upon information available to the Agency at this time (i.e., information in your application and the status of current good manufacturing practices of the facilities used in manufacturing and testing of the drug product) and is, therefore, subject to change on the basis of any new information that may come to our attention.

Your application contains certifications to each of the patents under section 505(b)(2)(A)(iv) of the Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of, this drug product under this application ("Paragraph IV certifications").

Section 505(c)(3)(C) of the Act provides that approval of a new drug application submitted pursuant to section 505(b)(2) of the Act shall be made effective immediately, unless an action is brought for infringement of one or more of the patents that were the subject of the paragraph IV certifications. This action must be taken prior to the expiration of forty-five days from the date the notice provided under section 505(b)(3) is received by the patent owner/approved application holder. You notified us that you complied with the requirements of section 505(b)(3) of the Act. In addition, you have notified the Agency that the patent owner and/or approved application holder has initiated a patent infringement suit against you with respect to patent 5,714,512 B1, and patent 5,750,561 B1 in the United States District Court for the District of Delaware (Aventis Pharma S.A., and sanofi-aventis U.S., LLC (collectively, "sanofi-aventis") vs. Hospira, Inc. [Civil Action Case No. 07-721]).

Therefore, final approval cannot be granted until:

1. a. expiration of the 30-month period provided for in Section 505(c)(3)(C) beginning on the date of receipt of the 45-day notice required under Section 505(b)(3), unless the court has extended or reduced the period because of the failure of either party to reasonably cooperate in expediting the action, or
- b. the date the court decides that the patent(s) is/are invalid or not infringed as described in section 505(c)(3)(C)(i), (ii), (iii,) or (iv) of the Act, or,
- c. the listed patent(s) has/have expired, and
2. we are assured there is no new information that would affect whether final approval should be granted.

In addition, the listed reference drug product upon which you base your application is subject to a period of patent protection and exclusivity protection and therefore, final approval of your application under section 505(c)(3) of the Act [21 U.S.C. 355(c)(3)] may not be made effective until the period has expired, i.e., September 28, 2010.

No more than 60 days prior to September 28, 2010, or when requested, submit an amendment to this application identifying changes, if any, in the conditions under which your product was tentatively approved. This information should include updated labeling, chemistry, manufacturing and controls data, and a safety update.

Failure to submit this amendment will prompt a review of the application that may result in rescission of the tentative approval letter.

Promotional materials should be submitted, in duplicate, directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

We note your plan, at the time of product launch, to inform healthcare practitioners about the differences in the preparation of the proposed Docetaxel Injection versus other docetaxel products (e.g., Dear Healthcare Professional letter), as per your August 8, 2008, correspondence.

Before we issue a final approval letter, this NDA is not deemed approved. If you believe that there are grounds for issuing the final approval letter before September 28, 2010, you should amend your application accordingly.

This product may be considered misbranded under the Federal Food, Drug, and Cosmetic Act if it is marketed with this change before final approval.

If you choose to use a proprietary name for this product, the name and its use in the labels must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit any proprietary name to the Agency for our review prior to its implementation.

If you have any questions, please call Frank Cross, Regulatory Project Manager, at (301) 796-0876.

Sincerely,

{See appended electronic signature page}

Ramzi Dagher, M.D.
Deputy Division Director
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure

53 Page(s) of Draft Labeling has been
Withheld in Full as B4 (CCI/TS)
immediately following this page

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Ramzi Dagher
8/11/2008 04:52:02 PM

Cross Jr, Frank H

From: Cross Jr, Frank H
Sent: Friday, August 08, 2008 11:20 AM
To: 'Zutkis, Judith'
Subject: NDA 22-234, Docetaxel

Dear Ms. Zutkis,

Please provide an agreement to the following:

At the time of product launch, you plan to inform healthcare practitioners about the differences in the preparation of the proposed Docetaxel Injection which has one dilution step versus other docetaxel products which require two dilution steps (e.g., Dear Healthcare Professional letter).

Thanks,

Frank

Frank Cross, M.A., MT (ASCP)
CAPT, USPHS Commissioned Corps
Chief, Project Management Staff
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
White Oak Building 22, Rm. 2110
10903 New Hampshire Blvd.
Silver Spring, MD 20993
Ph: 301-796-0876
Fax: 301-796-9845
e-mail: frank.crossjr@fda.hhs.gov



August 8, 2008

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration
Central Document Room
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

**NDA AMENDMENT – RESPONSE TO FDA TELEPHONE REQUEST FOR
UPDATED LABELING**

Hospira, Inc. herein responds to the Agency's telephone requests on August 5, 2008 and August 7, 2008 to submit revised carton labels and revised content of labeling in PLR format for NDA 22-234, Docetaxel Injection, 10 mg/mL vials in response to labeling deficiencies. Reference is made to the proposed labeling changes provided to Hospira as email notifications dated August 5, 2008 and August 7, 2008. The Agency's comments and Hospira's responses referencing the completed changes are attached.

Appended to the archival copy of this submission is a CD containing the container and carton labels as FPL and the MSWord version of the package insert (content of labeling) in PLR format. The files contained on the CD have been scanned for viruses using the current version of McAfee VirusScan Enterprise 8.0 virus scanning software.

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045



We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

Judith Zutkis
Director, Global Regulatory Affairs
Phone: (224) 212-4949
Fax: (224) 212-5401
e-mail: judith.zutkis@secure.hospira.com

1. Regarding the PI:

The 1st reference for Section 15 REFERENCES has been shortened. .

Please change NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165 to:

Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH Alert 2004-165.

Hospira, Inc. has updated the package insert to change the 1st reference in Section 15 REFERENCES as requested by the Agency.

2. Regarding your labeling submitted July 30, 2008, please revise the labeling to address the following issues:

Package Insert:

a) The sponsor should NOT include an (b) (4) for adverse event reporting in Highlights. The regulations allow for a dedicated website for AR reporting, but not an (b) (4) as it does not provide a structured format for reporting.

b) The revision date at the end of Highlights should be filled in with the date of approval of this label. Also, the brackets around the date should be removed.

c) Please develop a "Patient Counseling Section" under section 17 of the FPI. There should be a section 17.1 which summarizes the most important information that the prescriber should convey to the patient (under the Title "Information for Patients"). Consumer-friendly language should not be used. Section 17.2 should be the existing PPI, under the title "FDA-approved Patient Labeling." These new subsections (17.1 and 17.2) will also need to be added to Contents.

d) In the title for section 17 in the FPI, there should be no period after "17"

e) In Highlights, the formatting should be consistent throughout, i.e.:

- No period should be at the end of the product title line in Highlights (the line immediately above the "Initial U.S. Approval" line)

- **All of the indented bullets in Highlights need to be revised. The sponsor's version has the text wrapping around to the left margin when the bulleted text has more than one line. The version we sent has the entire text of a bullet indented, which is much easier to read.**
 - **Three places in Highlights have extra white space (an extra hard return) that should be deleted. One in D&A (after the first line), one at the end of D&A, and one in Adverse Reactions (between the 2 paragraphs).**
- f) Because Highlights and Contents do not all fit on page 1, Highlights only should appear on page 1, with Contents beginning on page 2. This will make Contents all appear on one page, rather than splitting it between pages.**

Cartons:

We acknowledge your increase of the statement: "For IV Infusion only" Please increase the prominence again.

Hospira acknowledges the Agency comments and has made the following changes to the Package Insert and Carton:

- We have removed the (b) (4) for adverse events reporting from the Highlights
- We have reformatted the date at the end of the highlights to xx/yyyy and removed the brackets. Updated labeling will be submitted exhibiting the data of full approval with FPL.
- A Patient Counseling Section has been created including subsection 17.1 "Information for Patients". See revised content of labeling included with this amendment.
- All formatting issues have been updated
- The Highlights and Contents have been separated to two (2) separate pages.

The prominence of the statement "For IV Infusion Only" has been increased on the carton as requested.

3. Please add the following line immediately after the line "17 Patient Counseling Information" (before the header for 17.1):

See FDA-Approved Patient Labeling (17.2)

The currently approved PPI is what goes under 17.2.

The statement has been added as requested.

4. Titles of 17.1 and 17.2 are okay.

Bullet all items

Please replace the 1st comment regarding pregnancy in the Patient Draft Counseling with the following

Docetaxel Injection may cause fetal harm. (b) (4)
Women of childbearing potential should use effective contraceptives if taking Docetaxel Injection [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1)].

Each statement in 17.1 “Information for Patients” has been bulleted. The 1st comment has been updated to match the proposed statement above.

5. Please also incorporate the following labeling revision into the Package Insert:

Ensure that the unit of measure follows the first numerical value when expressing dosage ranges (e.g., “60 mg -100 mg/m²” or “60 mg to 100 mg/m²”).

Te unit of measure has been added to the first numerical value when expressing dosage ranges.

53 Page(s) of Draft Labeling has been Withheld in Full as B4 (CCI/TS) immediately following this page



August 8, 2008

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research
Food and Drug Administration
Central Document Room (CDR)
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

GENERAL CORRESPONDENCE

RESPONSE TO FDA TELEPHONE QUERIES

Hospira, Inc. herein responds to the Agency's telephone request on August 8, 2008 for NDA 22-234, Docetaxel Injection, 10 mg/mL vials. Attached are the Agency's comments with Hospira, Inc.'s responses.

We note that labeling deficiencies also received on August 5 and August 7, 2008 will be submitted separately as an amendment to the pending application.

We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045




Sincerely,

HOSPIRA, INC.

A handwritten signature in black ink that reads "Judith Zutkis".

Judith Zutkis
Director, Global Regulatory Affairs
Phone: (224) 212-4949
Fax: (224) 212-5401
e-mail: judith.zutkis@secure.hospira.com

This application contains the following items: (Check all that apply)		
<input checked="" type="checkbox"/>	1. Index	
<input type="checkbox"/>	2. Labeling (check one)	<input type="checkbox"/> Draft Labeling <input type="checkbox"/> Final Printed Labeling
<input type="checkbox"/>	3. Summary (21 CFR 314.50 (c))	
<input type="checkbox"/>	4. Chemistry section	
	A. Chemistry, manufacturing, and controls information (e.g., 21 CFR 314.50(d)(1); 21 CFR 601.2)	
	B. Samples (21 CFR 314.50 (e)(1); 21 CFR 601.2 (a)) (Submit only upon FDA's request)	
	C. Methods validation package (e.g., 21 CFR 314.50(e)(2)(i); 21 CFR 601.2)	
<input type="checkbox"/>	5. Nonclinical pharmacology and toxicology section (e.g., 21 CFR 314.50(d)(2); 21 CFR 601.2)	
<input type="checkbox"/>	6. Human pharmacokinetics and bioavailability section (e.g., 21 CFR 314.50(d)(3); 21 CFR 601.2)	
<input type="checkbox"/>	7. Clinical Microbiology (e.g., 21 CFR 314.50(d)(4))	
<input type="checkbox"/>	8. Clinical data section (e.g., 21 CFR 314.50(d)(5); 21 CFR 601.2)	
<input type="checkbox"/>	9. Safety update report (e.g., 21 CFR 314.50(d)(5)(vi)(b); 21 CFR 601.2)	
<input type="checkbox"/>	10. Statistical section (e.g., 21 CFR 314.50(d)(6); 21 CFR 601.2)	
<input type="checkbox"/>	11. Case report tabulations (e.g., 21 CFR 314.50(f)(1); 21 CFR 601.2)	
<input type="checkbox"/>	12. Case report forms (e.g., 21 CFR 314.50 (f)(2); 21 CFR 601.2)	
<input type="checkbox"/>	13. Patent information on any patent which claims the drug (21 U.S.C. 355(b) or (c))	
<input type="checkbox"/>	14. A patent certification with respect to any patent which claims the drug (21 U.S.C. 355 (b)(2) or (j)(2)(A))	
<input type="checkbox"/>	15. Establishment description (21 CFR Part 600, if applicable)	
<input type="checkbox"/>	16. Debarment certification (FD&C Act 306 (k)(1))	
<input type="checkbox"/>	17. Field copy certification (21 CFR 314.50 (l)(3))	
<input type="checkbox"/>	18. User Fee Cover Sheet (Form FDA 3397)	
<input type="checkbox"/>	19. Financial information (21 CFR Part 54)	
<input checked="" type="checkbox"/>	20. OTHER (Specify)	
CERTIFICATION		
I agree to update this application with new safety information about the product that may reasonably affect the statement of contraindications, warnings, precautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as requested by FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications, including, but not limited to the following:		
<ol style="list-style-type: none"> 1. Good manufacturing practice regulations in 21 CFR Parts 210, 211 or applicable regulations, Parts 606, and/or 820. 2. Biological establishment standards in 21 CFR Part 600. 3. Labeling regulations in 21 CFR Parts 201, 606, 610, 660, and/or 809. 4. In the case of a prescription drug or biological product, prescription drug advertising regulations in 21 CFR Part 202. 5. Regulations on making changes in application in FD&C Act section 506A, 21 CFR 314.71, 314.72, 314.97, 314.99, and 601.12. 6. Regulations on Reports in 21 CFR 314.80, 314.81, 600.80, and 600.81. 7. Local, state and Federal environmental impact laws. 		
If this application applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act, I agree not to market the product until the Drug Enforcement Administration makes a final scheduling decision.		
The data and information in this submission have been reviewed and, to the best of my knowledge are certified to be true and accurate.		
Warning: A willfully false statement is a criminal offense, U.S. Code, title 18, section 1001.		
SIGNATURE OF RESPONSIBLE OFFICIAL OR AGENT	TYPED NAME AND TITLE	DATE
	Judith Zutkis, Director, Global Regulatory Affairs	08/08/2008
ADDRESS (Street, City, State, and ZIP Code)	Telephone Number	
275 N. Field Dr., Lake Forest, IL 60045-5046	224-212-4949	
<p>Public reporting burden for this collection of information is estimated to average 24 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:</p>		
Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (HFD-143) Central Document Room 5901-B Amundson Road Beltsville, MD 20705-2166	Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (HFM-99) 1401 Rockville Pike Rockville, MD 20852-1448	An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.



DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Certification of Compliance, under 42 U.S.C. § 282(j)(5)(B), with
Requirements of ClinicalTrials.gov Data Bank (42 U.S.C. § 282(j))

(For submission with an application/submission, including amendments, supplements, and resubmissions, under §§ 505, 515, 520(m), or 510(k) of the Federal Food, Drug, and Cosmetic Act or § 351 of the Public Health Service Act.)

SPONSOR / APPLICANT / SUBMITTER INFORMATION

1. NAME OF SPONSOR/APPLICANT/SUBMITTER Hospira, Inc.	2. DATE OF THE APPLICATION/SUBMISSION WHICH THIS CERTIFICATION ACCOMPANIES 08/08/2008
3. ADDRESS (Number, Street, State, and ZIP Code) 275 N. Field Drive Dept. 0389, Bldg. H2-2 Lake Forest, IL 60045-5046	4. TELEPHONE AND FAX NUMBER (Include Area Code) (Tel.) 224-212-4949 (Fax) 224-212-5401

PRODUCT INFORMATION

5. FOR DRUGS/BIOLOGICS: Include Any/All Available Established, Proprietary and/or Chemical/Biochemical/Blood/Cellular/Gene Therapy Product Name(s)
FOR DEVICES: Include Any/All Common or Usual Name(s), Classification, Trade or Proprietary or Model Name(s) and/or Model Number(s)
(Attach extra pages as necessary)

Docetaxel Injection

(2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl ester, 13-ester
with 5β,- 20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-

11-en-9-one 4-acetate 2-benzoate

APPLICATION / SUBMISSION INFORMATION

6. TYPE OF APPLICATION/SUBMISSION WHICH THIS CERTIFICATION ACCOMPANIES

IND NDA ANDA BLA PMA HDE 510(k) PDP Other

7. INCLUDE IND/NDA/ANDA/BLA/PMA/HDE/510(k)/PDP/OTHER NUMBER (If number previously assigned)
22-234

8. SERIAL NUMBER ASSIGNED TO APPLICATION/SUBMISSION WHICH THIS CERTIFICATION ACCOMPANIES

CERTIFICATION STATEMENT / INFORMATION

9. CHECK ONLY ONE OF THE FOLLOWING BOXES (See instructions for additional information and explanation)

A. I certify that the requirements of 42 U.S.C. § 282(j), Section 402(j) of the Public Health Service Act, enacted by 121 Stat. 823, Public Law 110-85, do not apply because the application/submission which this certification accompanies does not reference any clinical trial.

B. I certify that the requirements of 42 U.S.C. § 282(j), Section 402(j) of the Public Health Service Act, enacted by 121 Stat. 823, Public Law 110-85, do not apply to any clinical trial referenced in the application/submission which this certification accompanies.

C. I certify that the requirements of 42 U.S.C. § 282(j), Section 402(j) of the Public Health Service Act, enacted by 121 Stat. 823, Public Law 110-85, apply to one or more of the clinical trials referenced in the application/submission which this certification accompanies and that those requirements have been met.

10. IF YOU CHECKED BOX C, IN NUMBER 9, PROVIDE THE NATIONAL CLINICAL TRIAL (NCT) NUMBER(S) FOR ANY "APPLICABLE CLINICAL TRIAL(S)," UNDER 42 U.S.C. § 282(j)(1)(A)(i), SECTION 402(j)(1)(A)(i) OF THE PUBLIC HEALTH SERVICE ACT, REFERENCED IN THE APPLICATION/ SUBMISSION WHICH THIS CERTIFICATION ACCOMPANIES (Attach extra pages as necessary)

NCT Number(s):

The undersigned declares, to the best of her/his knowledge, that this is an accurate, true, and complete submission of information. I understand that the failure to submit the certification required by 42 U.S.C. § 282(j)(5)(B), section 402(j)(5)(B) of the Public Health Service Act, and the knowing submission of a false certification under such section are prohibited acts under 21 U.S.C. § 331; section 301 of the Federal Food, Drug, and Cosmetic Act. Warning: A willfully and knowingly false statement is a criminal offense, U.S. Code, title 18, section 1001.

11. SIGNATURE OF SPONSOR/APPLICANT/SUBMITTER OR AN AUTHORIZED REPRESENTATIVE (Sign) 	12. NAME AND TITLE OF THE PERSON WHO SIGNED IN NO. 11 (Name) Judith Zulkis (Title) Director, Global Regulatory Affairs
13. ADDRESS (Number, Street, State, and ZIP Code) (of person identified in No. 11 and 12) 275 N. Field Drive Dept. 0389, Bldg. H2-2 Lake Forest, IL 60045-5046	14. TELEPHONE AND FAX NUMBER (Include Area Code) (Tel.) 224-212-4949 (Fax) 224-212-5401
	15. DATE OF CERTIFICATION 08/08/2008



Please provide an agreement to the following:

At the time of product launch, you plan to inform healthcare practitioners about the differences in the preparation of the proposed Docetaxel Injection which has one dilution step versus other docetaxel products which require two dilution steps (e.g., Dear Healthcare Professional letter).

Hospira, Inc. commits that at the time of product launch, we will inform the healthcare practitioners about the differences in the preparation of the proposed Docetaxel Injection, which has one dilution step versus other Docetaxel products which require two dilution steps (e.g., a Dear Healthcare Profession letter).



August 8, 2008

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research
Food and Drug Administration
Central Document Room (CDR)
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

GENERAL CORRESPONDENCE

RESPONSE TO FDA TELEPHONE QUERIES

Hospira, Inc. herein responds to the Agency's telephone request on August 8, 2008 for NDA 22-234, Docetaxel Injection, 10 mg/mL vials. Attached are the Agency's comments with Hospira, Inc.'s responses.

We note that labeling deficiencies also received on August 5 and August 7, 2008 will be submitted separately as an amendment to the pending application.

We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045

Robert L. Justice, M.D.
Page 2 of 2



Sincerely,

HOSPIRA, INC.

A handwritten signature in black ink that reads "Judith Zutkis".

Judith Zutkis
Director, Global Regulatory Affairs
Phone: (224) 212-4949
Fax: (224) 212-5401
e-mail: judith.zutkis@secure.hospira.com



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 22-234

Hospira, Inc.
Attention: Judith Zutkis
Director, Global Regulatory Affairs
275 N. Field Drive
D-0389, Bldg H2-2N
Lake Forest, IL 60045-5046

Dear Ms. Zutkis:

Please refer to your new drug application dated July 9, 2007, received July 11, 2007, submitted under section pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Docetaxel Injection, 20 mg/2 mL single-dose vial, 80 mg/8 mL multi-dose vial, 160 mg/16 mL multi-dose vial.

On April 28, 2008, we received your April 24, 2008, major amendment to this application. The receipt date is within 3 months of the user fee goal date. Therefore, we are extending the goal date by three months to provide time for a full review of the submission. The extended user fee goal date is August 11, 2008.

If you have any questions, call me at 301-796-0876.

Sincerely,

{See appended electronic signature page}

Frank H. Cross, Jr
Chief, Project Management Staff
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Frank Cross

8/4/2008 09:01:34 AM



April 24, 2008

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration
Central Document Room
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

AMENDMENT - RESPONSE TO LABELING DEFICIENCIES

Hospira, Inc. herein responds to the Agency's email request on March 06, 2008 with Labeling deficiencies for NDA 22-234, Docetaxel Injection, 10 mg/mL vials. Attached are the Agency's comments with Hospira, Inc.'s responses

A CD containing response to FDA comments in MS Word compatible format, FPL of revised container and carton labeling in PDF format, and a side-by-side comparison of Hospira's previously submitted container and carton labeling versus revised container and carton labeling are appended to the archival copy of this submission. The files contained on the CD have been scanned for viruses using the current version of McAfee VirusScan Enterprise 8.0 virus scanning software.

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045



We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

A handwritten signature in black ink that reads "Judith Zutkis".

Judith Zutkis
Director, Global Regulatory Affairs
Phone: (224) 212-4949
Fax: (224) 212-5401
e-mail: judith.zutkis@secure.hospira.com

cc: Frank Cross, Jr., M.A., MT (ASCP)



Labeling Deficiencies

The Agency's comments and Hospira's responses are included below.

General

- 1. A proprietary name is preferred to distinguish this product from Taxotere and avoid preparation errors.**

Hospira acknowledges the Agency's request to add a proprietary name to distinguish this product from Taxotere. Given that this is a generic product, that standard naming conventions for generic products is to use the established name and that Hospira has requested that its Docetaxel Injection be determined as therapeutically equivalent upon approval, Hospira would propose to maintain "Docetaxel Injection" as its product name. Additionally, selection of proprietary names is typically a lengthy process to insure that any selected name would not cause confusion with other unrelated products on the market and be commercially acceptable. (b) (4)

Hospira's Docetaxel Injection are clearly displayed on the side panel of the carton, with full instructions included in the package insert.

Carton

- 1. Increase prominence of "Rx only"**

The prominence of "Rx only" has been increased.

- 2. Increase prominence of "For IV Infusion only"**

The prominence of "For IV Infusion only" has been increased.

- 3. Increase prominence of (b) (4).**

The prominence of (b) (4) has been increased.

- 4. Increase prominence of (b) (4)**

The prominence of (b) (4) has been increased.



5. Indicate where on the label the expiration date and lot number will be printed

The text “Lot/Exp. Area” has been added to note placement of Lot and Expiry information on the printed label.

6. Change [REDACTED] (b) (4) to “Retain in original package to protect from light”

The term “Retain in original package to protect from light” has been added to the side panel.

7. Remove or change graphic around strength (looks like a capsule, may cause confusion)

The graphic around strength is a standard style guide graphic that Hospira, Inc. uses for all its oncology products in the US. As removal of this graphic would result in a differentiation for this specific Hospira oncology product from the rest its oncology product line, Hospira proposes to keep the graphic around strength.

8. Add [REDACTED] (b) (4)

The statement [REDACTED] (b) (4) has been added to the side panel.

9. Add (to a side panel) [REDACTED] (b) (4)

An [REDACTED] (b) (4) has been added to a side panel.

10. Add [REDACTED] (b) (4)

The statement [REDACTED] (b) (4) has been added to a side panel.



11. Multidose vials needs additional instruction for storage after 1st use, i.e. “Docetaxel Injection (b) (4) vials are stable for up to 28 days when stored between 2 and 8 °C (36 and 46 °F) and protected from light”

For multi-dose configurations, instructions for storage after 1st use, as suggested by the Agency have been added to a side panel.

12. Need better differentiation between strengths, eg., use different colors to indicate strengths

Hospira has color-coded the graphic around the strength on the front panel and additionally around the vial graphic on each panel to differentiate between strengths.

Vial

General Comment:

“In accordance with CFR 201.10(h)(2)(i), whereby it state “A drug packaged in a container too small or otherwise unable to accommodate a label with sufficient space to bear the information required for compliance with section 502(e)(1)(A)(ii) and (B) of the act shall be exempt from compliance with those clauses: *Provided, That:*

- (1) The label bears:
 - (i) The proprietary name of the drug;
 - (ii) The established name, if such there be, of the drug;
 - (iii) An identifying lot or control number; and
 - (iv) The name of the manufacturer, packer, or distributor of the drug; and
- (2) All the information required to appear on the label by the act and the regulations in this chapter appears on the carton or other outer container or wrapper, if such carton, outer container or wrapper has sufficient space to bear such information, or such complete label information appears on a leaflet with the package.”

Hospira has attempted to satisfactorily increase the prominence or add additional language to the container label as requested by the Agency as space on the container label allows. In those instances where the prominence may still be in question or language omitted, it is due to lack of space on the label due to vial size and said language is included on the carton.



1. Clarify RA number. What is it? Why is it there? Consider removing if only a label part number

RL number is the Hospira commodity number by which we track the version of the label as submitted to the Agency. Where space allows, Hospira has determined to keep this commodity number on the label.

2. Increase prominence of “Rx only”

The prominence of “Rx only” has been increased.

3. Increase prominence of “For IV Infusion only”

The prominence of “For IV Infusion only” has been increased.

4. Increase prominence of “Sterile”

The prominence of “Sterile” has been increased.

5. Increase prominence of [REDACTED] (b)(4)

The prominence of [REDACTED] (b)(4) has been increased.

6. Indicate where on the label the expiration date and lot number will be printed

The text “Lot/Exp. Area” has been added to note placement of Lot and Expiry information on the printed label.

7. Remove or change graphic around strength (looks like a capsule, may cause confusion)

The graphic around strength is a standard style guide graphic that Hospira, Inc. uses for all its oncology products in the US. As removal of this graphic would result in a differentiation for this specific Hospira oncology product from the rest its oncology product line, Hospira proposes to keep the graphic around strength.



8. Multidose vials needs additional instruction for storage after 1st use, i.e.

(b) (4)

Per the CFR section cited above in general comment, there is inadequate space on the container label to include this instruction. Verbiage has been added to the carton label.

9. Need better differentiation between strengths, eg., use different colors to indicate strengths

Hospira has color-coded the graphic around the strength and established name to differentiate between strengths.



November 15, 2007

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration
Central Document Room
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

**NDA AMENDMENT – RESPONSE TO FDA TELEPHONE REQUEST FOR
UPDATED PLR LABELING**

Hospira, Inc. herein responds to the Agency's telephone request on October 19, 2007 to submit updated labeling in PLR format for NDA 22-234, Docetaxel Injection, 10 mg/mL vials to match the reference listed drug (RLD) labeling in PLR format which was approved on September 28, 2007. Reference is also made to Hospira's e-mail communication with the FDA on October 22, 2007 in which we committed to respond to the Agency's telephone request by November 15, 2007. A copy of this e-mail communication is provided herein.

Appended to the archival copy of this submission is a CD containing:

- Microsoft Word version of Hospira's draft package insert in PLR format
- PDF of the current package insert for the RLD, TAXOTERE[®] Injection Concentrate

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045



- Side-by-side comparison of Hospira's draft package insert versus the RLD package insert in PDF format

Hospira will submit Structured Product Labeling (SPL) of Hospira's draft package insert in PLR format in a separate submission. The files contained on the CD have been scanned for viruses using the current version of McAfee VirusScan Enterprise 8.0 virus scanning software.

Hospira notes that the current package insert for TAXOTERE[®] Injection Concentrate, approved on September 28, 2007, includes an expanded indication for head and neck cancer for which a three-year period of marketing exclusivity has been granted. Hospira has elected to omit this expanded indication from our draft labeling, and therefore the additional marketing exclusivity is not applicable to Hospira's proposed Docetaxel Injection product. An updated Patent Certification and Exclusivity Statement and a copy of the Patent and Exclusivity Data from the current electronic edition of "The Orange Book" are included with this amendment.

We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

A handwritten signature in black ink that reads "Mary Pontikes".

Mary Pontikes
Sr. Associate, Global Regulatory Affairs
Phone: (224) 212-4852
Fax: (224) 212-5401
e-mail: mary.pontikes@secure.hospira.com

61 Page(s) of Draft Labeling has been
Withheld in Full as B4 (CCI/TS)
immediately following this page

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Frank Cross
2/7/2008 02:29:14 PM
MS Word File to Follow

REQUEST FOR CONSULTATION

TO (Division/Office):

CDER OSE CONSULTS

FROM: DDOP/Frank Cross, PM

DATE 2/7/08	IND NO.	NDA NO. 22-234	TYPE OF DOCUMENT New NDA - 505(b)(2)	DATE OF DOCUMENT 7/11/07
NAME OF DRUG Docetaxel Injection, 10 mg/mL vials		PRIORITY CONSIDERATION S	CLASSIFICATION OF DRUG 5	DESIRED COMPLETION DATE Target Date: 4/15/08 PDUFA Date: 5/11/08

NAME OF FIRM:

REASON FOR REQUEST

I. GENERAL

- | | | |
|--|--|---|
| <input type="checkbox"/> NEW PROTOCOL | <input type="checkbox"/> PRE--NDA MEETING | <input type="checkbox"/> RESPONSE TO DEFICIENCY LETTER |
| <input type="checkbox"/> PROGRESS REPORT | <input type="checkbox"/> END OF PHASE II MEETING | <input type="checkbox"/> FINAL PRINTED LABELING |
| <input type="checkbox"/> NEW CORRESPONDENCE | <input type="checkbox"/> RESUBMISSION | <input type="checkbox"/> LABELING REVISION |
| <input type="checkbox"/> DRUG ADVERTISING | <input type="checkbox"/> SAFETY/EFFICACY | <input type="checkbox"/> ORIGINAL NEW CORRESPONDENCE |
| <input type="checkbox"/> ADVERSE REACTION REPORT | <input type="checkbox"/> PAPER NDA | <input type="checkbox"/> FORMULATIVE REVIEW |
| <input type="checkbox"/> MANUFACTURING CHANGE/ADDITION | <input type="checkbox"/> CONTROL SUPPLEMENT | <input checked="" type="checkbox"/> OTHER (SPECIFY BELOW): Trade name review |
| <input type="checkbox"/> MEETING PLANNED BY | | |

II. BIOMETRICS

STATISTICAL EVALUATION BRANCH	STATISTICAL APPLICATION BRANCH
<input type="checkbox"/> TYPE A OR B NDA REVIEW <input type="checkbox"/> END OF PHASE II MEETING <input type="checkbox"/> CONTROLLED STUDIES <input type="checkbox"/> PROTOCOL REVIEW <input type="checkbox"/> OTHER (SPECIFY BELOW):	<input type="checkbox"/> CHEMISTRY REVIEW <input type="checkbox"/> PHARMACOLOGY <input type="checkbox"/> BIOPHARMACEUTICS <input type="checkbox"/> OTHER (SPECIFY BELOW):

III. BIOPHARMACEUTICS

- | | |
|--|---|
| <input type="checkbox"/> DISSOLUTION | <input type="checkbox"/> DEFICIENCY LETTER RESPONSE |
| <input type="checkbox"/> BIOAVAILABILITY STUDIES | <input type="checkbox"/> PROTOCOL-BIOPHARMACEUTICS |
| <input type="checkbox"/> PHASE IV STUDIES | <input type="checkbox"/> IN-VIVO WAIVER REQUEST |

IV. DRUG EXPERIENCE

- | | |
|--|--|
| <input type="checkbox"/> PHASE IV SURVEILLANCE/EPIDEMIOLOGY PROTOCOL | <input type="checkbox"/> REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY |
| <input type="checkbox"/> DRUG USE e.g. POPULATION EXPOSURE, ASSOCIATED DIAGNOSES | <input type="checkbox"/> SUMMARY OF ADVERSE EXPERIENCE |
| <input type="checkbox"/> CASE REPORTS OF SPECIFIC REACTIONS (List below) | <input type="checkbox"/> POISON RISK ANALYSIS |
| <input type="checkbox"/> COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP | |

V. SCIENTIFIC INVESTIGATIONS

- | | |
|-----------------------------------|--------------------------------------|
| <input type="checkbox"/> CLINICAL | <input type="checkbox"/> PRECLINICAL |
|-----------------------------------|--------------------------------------|

COMMENTS/SPECIAL INSTRUCTIONS: Even though this the Applicant will use the the established name for this product, please advise if DMETS review is appropriate, per CMC TL

PDUFA DATE: 5/11/08

ATTACHMENTS: Draft Package Insert, Container and Carton Labels

CC: Archival IND/NDA 22-234

HFD-150/Division File

HFD-150/RPM

HFD-150/Reviewers and Team Leaders

NAME AND PHONE NUMBER OF REQUESTER Frank Cross, 301-796-0876	METHOD OF DELIVERY (Check one) <input checked="" type="checkbox"/> DFS ONLY <input type="checkbox"/> MAIL <input type="checkbox"/> HAND
SIGNATURE OF RECEIVER	SIGNATURE OF DELIVERER

APPEARS THIS WAY ON ORIGINAL





November 15, 2007

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration
Central Document Room
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

**NDA AMENDMENT – RESPONSE TO FDA TELEPHONE REQUEST FOR
UPDATED PLR LABELING**

Hospira, Inc. herein responds to the Agency's telephone request on October 19, 2007 to submit updated labeling in PLR format for NDA 22-234, Docetaxel Injection, 10 mg/mL vials to match the reference listed drug (RLD) labeling in PLR format which was approved on September 28, 2007. Reference is also made to Hospira's e-mail communication with the FDA on October 22, 2007 in which we committed to respond to the Agency's telephone request by November 15, 2007. A copy of this e-mail communication is provided herein.

Appended to the archival copy of this submission is a CD containing:

- Microsoft Word version of Hospira's draft package insert in PLR format
- PDF of the current package insert for the RLD, TAXOTERE[®] Injection Concentrate

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045



- Side-by-side comparison of Hospira's draft package insert versus the RLD package insert in PDF format

Hospira will submit Structured Product Labeling (SPL) of Hospira's draft package insert in PLR format in a separate submission. The files contained on the CD have been scanned for viruses using the current version of McAfee VirusScan Enterprise 8.0 virus scanning software.

Hospira notes that the current package insert for TAXOTERE[®] Injection Concentrate, approved on September 28, 2007, includes an expanded indication for head and neck cancer for which a three-year period of marketing exclusivity has been granted. Hospira has elected to omit this expanded indication from our draft labeling, and therefore the additional marketing exclusivity is not applicable to Hospira's proposed Docetaxel Injection product. An updated Patent Certification and Exclusivity Statement and a copy of the Patent and Exclusivity Data from the current electronic edition of "The Orange Book" are included with this amendment.

We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

A handwritten signature in black ink that reads "Mary Pontikes".

Mary Pontikes
Sr. Associate, Global Regulatory Affairs
Phone: (224) 212-4852
Fax: (224) 212-5401
e-mail: mary.pontikes@secure.hospira.com

61 Page(s) of Draft Labeling has been
Withheld in Full as B4 (CCI/TS)
immediately following this page

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Frank Cross
2/7/2008 02:23:13 PM
MS Word file to follow by e-mail

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION		REQUEST FOR CONSULTATION			
TO (Division/Office): SEALD - Elizabeth Thompson			FROM: DDOP/Frank Cross		
DATE: 2/7/08	IND NO.:	NDA NO.: 22-234	TYPE OF DOCUMENT : New NDA - 505(b)(2)	DATE OF DOCUMENT: 7/11/07	
NAME OF DRUG: Docetaxel Injection, 10 mg/mL vials		PRIORITY CONSIDERATION: S	CLASSIFICATION OF DRUG: 5	DESIRED COMPLETION DATE: Target date: 4/15/08 PDUFA Date: 5/11/08	
NAME OF FIRM: Hospira, Inc.					
REASON FOR REQUEST					
I. GENERAL					
<input type="checkbox"/> PROGRESS REPORT <input type="checkbox"/> NEW CORRESPONDENCE <input type="checkbox"/> DRUG ADVERTISING <input type="checkbox"/> ADVERSE REACTION REPORT <input type="checkbox"/> MANUFACTURING CHANGE/ADDITION <input type="checkbox"/> MEETING PLANNED BY		<input type="checkbox"/> PRE--NDA MEETING <input type="checkbox"/> END OF PHASE II MEETING <input type="checkbox"/> RESUBMISSION <input type="checkbox"/> SAFETY/EFFICACY <input type="checkbox"/> PAPER NDA <input type="checkbox"/> CONTROL SUPPLEMENT		<input type="checkbox"/> RESPONSE TO DEFICIENCY LETTER <input type="checkbox"/> FINAL PRINTED LABELING <input type="checkbox"/> LABELING REVISION <input type="checkbox"/> ORIGINAL NEW CORRESPONDENCE <input type="checkbox"/> FORMULATIVE REVIEW <input type="checkbox"/> OTHER (SPECIFY BELOW):	
II. BIOMETRICS					
STATISTICAL EVALUATION BRANCH			STATISTICAL APPLICATION BRANCH		
<input type="checkbox"/> TYPE A OR B NDA REVIEW <input type="checkbox"/> END OF PHASE II MEETING <input type="checkbox"/> CONTROLLED STUDIES <input type="checkbox"/> PROTOCOL REVIEW <input type="checkbox"/> OTHER:			<input type="checkbox"/> CHEMISTRY REVIEW <input type="checkbox"/> PHARMACOLOGY <input type="checkbox"/> BIOPHARMACEUTICS <input type="checkbox"/> OTHER:		
III. BIOPHARMACEUTICS					
<input type="checkbox"/> DISSOLUTION <input type="checkbox"/> BIOAVAILABILITY/PK STUDIES <input type="checkbox"/> PHASE IV STUDIES			<input type="checkbox"/> DEFICIENCY LETTER RESPONSE <input type="checkbox"/> PROTOCOL-BIOPHARMACEUTICS <input type="checkbox"/> IN-VIVO WAIVER REQUEST		
IV. DRUG EXPERIENCE					
<input type="checkbox"/> PHASE IV SURVEILLANCE/EPIDEMIOLOGY PROTOCOL <input type="checkbox"/> DRUG USE e.g. POPULATION EXPOSURE, ASSOCIATED DIAGNOSES <input type="checkbox"/> CASE REPORTS OF SPECIFIC REACTIONS (List below) <input type="checkbox"/> COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP			<input type="checkbox"/> REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY <input type="checkbox"/> SUMMARY OF ADVERSE EXPERIENCE <input type="checkbox"/> POISON RISK ANALYSIS		
V. SCIENTIFIC INVESTIGATIONS					
<input type="checkbox"/> CLINICAL			<input type="checkbox"/> PRECLINICAL		
COMMENTS/SPECIAL INSTRUCTIONS: Please review this new NDA in terms of SEALD. Have already done PM Labeling review. RLD is approved.					
Thanks, Frank					
SIGNATURE OF REQUESTER: Frank Cross			METHOD OF DELIVERY (Check one): MAIL X DFS		
SIGNATURE OF RECEIVER:			SIGNATURE OF DELIVERER:		



November 15, 2007

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration
Central Document Room
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

**NDA AMENDMENT – RESPONSE TO FDA TELEPHONE REQUEST FOR
UPDATED PLR LABELING**

Hospira, Inc. herein responds to the Agency's telephone request on October 19, 2007 to submit updated labeling in PLR format for NDA 22-234, Docetaxel Injection, 10 mg/mL vials to match the reference listed drug (RLD) labeling in PLR format which was approved on September 28, 2007. Reference is also made to Hospira's e-mail communication with the FDA on October 22, 2007 in which we committed to respond to the Agency's telephone request by November 15, 2007. A copy of this e-mail communication is provided herein.

Appended to the archival copy of this submission is a CD containing:

- Microsoft Word version of Hospira's draft package insert in PLR format
- PDF of the current package insert for the RLD, TAXOTERE[®] Injection Concentrate

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045



- Side-by-side comparison of Hospira's draft package insert versus the RLD package insert in PDF format

Hospira will submit Structured Product Labeling (SPL) of Hospira's draft package insert in PLR format in a separate submission. The files contained on the CD have been scanned for viruses using the current version of McAfee VirusScan Enterprise 8.0 virus scanning software.

Hospira notes that the current package insert for TAXOTERE[®] Injection Concentrate, approved on September 28, 2007, includes an expanded indication for head and neck cancer for which a three-year period of marketing exclusivity has been granted. Hospira has elected to omit this expanded indication from our draft labeling, and therefore the additional marketing exclusivity is not applicable to Hospira's proposed Docetaxel Injection product. An updated Patent Certification and Exclusivity Statement and a copy of the Patent and Exclusivity Data from the current electronic edition of "The Orange Book" are included with this amendment.

We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

A handwritten signature in black ink that reads "Mary Pontikes".

Mary Pontikes
Sr. Associate, Global Regulatory Affairs
Phone: (224) 212-4852
Fax: (224) 212-5401
e-mail: mary.pontikes@secure.hospira.com

55 Page(s) of Draft Labeling has been
Withheld in Full as B4 (CCI/TS)
immediately following this page

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Frank Cross
2/7/2008 02:31:24 PM
MS Word file to follow by e-mail

From: Cross Jr, Frank H
Sent: Tuesday, February 05, 2008 4:52 PM
To: 'judith.zutkis@secure.hospira.com'
Subject: NDA 22-234, CMC Information Request

Importance: High

Attachments: 22234_CMC_IR1.doc


Dear Ms. Zutkis,

Please provide a response to following CMC issues right away.

Thanks,

Frank

NDA 22-234: CMC Information Request

1. The Drug Master File ^{(b)(4)}, for the drug substance, Docetaxel, has been found to be inadequate to support the NDA. A letters detailing the deficiencies has been issued to the designated agent. Please work with them to quickly resolve these issues.
2. Provide the USAN and if available IUPAC name for the drug substance.
3. Clarify whether your SOP for the storage and handling of dehydrated alcohol ensures protection against moisture ingress. Presence of significant amounts of moisture in the alcohol may affect the drug product stability.
4. It is noted that maximum manufacturing times have been established ^{(b)(4)}

5. Discuss the potential loss of alcohol during the manufacturing process and how this might vary as the batch size is increased to commercial scale. Also discuss why the amount of alcohol present in batch S012258RA was lower than that in S032260RA at the initial time point.

6. Insufficient justification has been provided to identify (b)(4) as a process impurity for the drug substance. Therefore, establish limits for this impurity and included in the drug product specification. Alternatively, provide sufficient justification demonstrating the levels of (b)(4) do not change over the proposed retest period for the drug substance and the proposed shelf-life of the product or upon forced degradation.
7. In regards to section 3.2.P.5.3.3, Determination of Ethanol in Docetaxel Injection by GC:
 - a. Given the initial failure for intermediate precision, provide the data generated to demonstrate that intermediate precision is acceptable.
 - b. The line of best fit for Figure 17 appears to be hand drawn or a misprinted. Provide the appropriate figure or alternatively provide the mathematical model for the current line of best fit.
8. The stability data provided in the NDA does not support the proposed (b)(4) expiration dating. Provide stability updates for the primary stability batches in SAS transport files or Excel spreadsheet format and statistical analysis of all stability-indicating quality attributes. This should also include the results of anti-microbial preservative effectiveness testing USP<51>.
9. In view of potential interaction of the formulation with syringe piston, provide a justification whether any specific syringes should be used to transfer the injection concentrate into infusion bags.
10. There is a potential for interaction of the formulation with the contact systems that are part of the fluid path during the manufacture and dispensing of the drug product. Provide the following additional information to support the fitness for use of the contact systems.
 - (i) Identity of (b)(4) and their toxicological qualifications.
 - (ii) Information on the extractables and leachables from (b)(4) syringes.
11. It appears that the analytical methods were validated at one site and transferred to another site. Provide adequate documentation including site transfer protocols and results to demonstrate that the analytical methods were successfully transferred to the new site.

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Frank Cross
2/5/2008 05:58:07 PM
CSO



November 20, 2007

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration
Central Document Room
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

**NDA AMENDMENT – RESPONSE TO FDA TELEPHONE REQUEST FOR
UPDATED PLR LABELING (SPL)**

Hospira, Inc. herein responds to the Agency's telephone request on October 19, 2007 to submit updated labeling in PLR format for NDA 22-234, Docetaxel Injection, 10 mg/mL vials to match the reference listed drug (RLD) labeling in PLR format which was approved on September 28, 2007. Reference is also made to Hospira, Inc.'s submission of November 15, 2007, "NDA Amendment – Response to FDA Telephone Request for Updated PLR Labeling," which contains a Microsoft Word version of Hospira's draft package insert in PLR format, a side-by-side comparison of Hospira's draft package insert versus the RLD package insert in PDF format, and our commitment to provide Structured Product Labeling (SPL) in a separate submission.

Appended to the archival copy of this submission is a CD containing the SPL version of the draft package insert in PLR format. The files contained on the CD have been scanned for viruses using the current version of McAfee VirusScan Enterprise 8.0 virus scanning software.

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045

Robert L. Justice, M.D.
Page 2 of 2
November 20, 2007



We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

A handwritten signature in cursive script that reads "Mary Pontikes".

Mary Pontikes
Sr. Associate, Global Regulatory Affairs
Phone: (224) 212-4852
Fax: (224) 212-5401
e-mail: mary.pontikes@secure.hospira.com



November 15, 2007

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration
Central Document Room
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

**NDA AMENDMENT – RESPONSE TO FDA TELEPHONE REQUEST FOR
UPDATED PLR LABELING**

Hospira, Inc. herein responds to the Agency's telephone request on October 19, 2007 to submit updated labeling in PLR format for NDA 22-234, Docetaxel Injection, 10 mg/mL vials to match the reference listed drug (RLD) labeling in PLR format which was approved on September 28, 2007. Reference is also made to Hospira's e-mail communication with the FDA on October 22, 2007 in which we committed to respond to the Agency's telephone request by November 15, 2007. A copy of this e-mail communication is provided herein.

Appended to the archival copy of this submission is a CD containing:

- Microsoft Word version of Hospira's draft package insert in PLR format
- PDF of the current package insert for the RLD, TAXOTERE[®] Injection Concentrate

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045



- Side-by-side comparison of Hospira's draft package insert versus the RLD package insert in PDF format

Hospira will submit Structured Product Labeling (SPL) of Hospira's draft package insert in PLR format in a separate submission. The files contained on the CD have been scanned for viruses using the current version of McAfee VirusScan Enterprise 8.0 virus scanning software.

Hospira notes that the current package insert for TAXOTERE[®] Injection Concentrate, approved on September 28, 2007, includes an expanded indication for head and neck cancer for which a three-year period of marketing exclusivity has been granted. Hospira has elected to omit this expanded indication from our draft labeling, and therefore the additional marketing exclusivity is not applicable to Hospira's proposed Docetaxel Injection product. An updated Patent Certification and Exclusivity Statement and a copy of the Patent and Exclusivity Data from the current electronic edition of "The Orange Book" are included with this amendment.

We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

A handwritten signature in cursive script that reads "Mary Pontikes".

Mary Pontikes
Sr. Associate, Global Regulatory Affairs
Phone: (224) 212-4852
Fax: (224) 212-5401
e-mail: mary.pontikes@secure.hospira.com

55 Page(s) of Draft Labeling has been
Withheld in Full as B4 (CCI/TS)
immediately following this page



September 27, 2007

Robert L. Justice, M.D.
Director, Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research
Food and Drug Administration
Central Document Room (CDR)
5901-B Ammendale Road
Beltsville, MD 20705-1266

**Re: Docetaxel Injection, 10 mg/mL Vials
NDA # 22-234**

**NDA AMENDMENT – RESPONSE TO FDA TELEPHONE REQUEST FOR PLR
LABELING**

Hospira, Inc. herein responds to the Agency's telephone request on September 6, 2007 regarding submission of labeling in PLR format for NDA 22-234, Docetaxel Injection, 10 mg/mL vials. Reference is also made to Hospira, Inc.'s submission of September 14, 2007, "NDA Amendment – Response to FDA telephone Queries," which contains additional administrative information as requested by the Agency along with Hospira, Inc.'s commitment to provide Docetaxel Injection labeling in PLR format in a separate submission.

Appended to the archival copy of this submission is a CD containing Structured Product Labeling (SPL) and Microsoft Word versions of the draft package insert in PLR format. The files contained on the CD have been scanned for viruses using the current version of McAfee VirusScan Enterprise 8.0 virus scanning software.

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045

Robert L. Justice, M.D.
Page 2 of 2
September 27, 2007



We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

A handwritten signature in cursive script that reads "Mary Pontikes".

Mary Pontikes
Sr. Associate, Global Regulatory Affairs
Phone: (224) 212-4852
Fax: (224) 212-5401
e-mail: mary.pontikes@secure.hospira.com

54 Page(s) of Draft Labeling has been
Withheld in Full as B4 (CCI/TS)
immediately following this page



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville, MD 20857

FILING COMMUNICATION

NDA 22-234

Hospira, Inc.
Attention: Mary Pontikes
Senior Associate, Global Regulatory Affairs
275 N. Field Drive
D-0389, Bldg H2-2N
Lake Forest, IL 60045-5046

Dear Ms. Pontikes:

Please refer to your July 9, 2007, new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Docetaxel Injection, 10mg/mL Vials.

We also refer to your submission dated September 14, 2007.

We have completed our filing review and have determined that your application is sufficiently complete to permit a substantive review. Therefore, this application has been filed under section 505(b) of the Act on September 9, 2007, in accordance with 21 CFR 314.101(a).

In our filing review, we have identified the following potential review issue:

The proposed labeling for this NDA was not submitted in the required Physician's Labeling Rule (PLR) format.

We are providing the above comments to give you preliminary notice of potential review issues. Our filing review is only a preliminary evaluation of the application and is not indicative of deficiencies that may be identified during our review. Issues may be added, deleted, expanded upon, or modified as we review the application.

We also request that you submit the following information:

Proposed labeling for this NDA in Physician's Labeling Rule (PLR) format.

Please respond only to the above request for additional information. While we anticipate that any response submitted in a timely manner will be reviewed during this review cycle, such review decisions will be made on a case-by-case basis at the time of receipt of the submission.

NDA 22-234

Page 2

If you have any questions, please call me at (301) 796-0876.

Sincerely,

{See appended electronic signature page}

Frank H. Cross, Jr.
Co-Chief, Project Management Staff
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Frank Cross

9/26/2007 10:44:39 AM



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville, MD 20857

NDA 22-234

NDA ACKNOWLEDGMENT

Hospira, Inc.
Attention: Mary Pontikes
Senior Associate, Global Regulatory Affairs
275 N. Field Drive
D-0389, Bldg H2-2N
Lake Forest, IL 60045-5046

Dear Ms. Pontikes:

We have received your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Docetaxel Injection, 10mg/mL Vials

Review Priority Classification: Standard (S)

Date of Application: July 9, 2007

Date of Receipt: July 11, 2007

Our Reference Number: NDA 22-234

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on September 9, 2007, in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be May 11, 2008.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have not fulfilled the requirements. We acknowledge receipt of your request for a waiver of pediatric studies for this application. Once the application has been filed we will notify you whether we have waived the pediatric study requirement for this application.

Please cite the NDA number listed above at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

NDA 22-234

Page 2

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Oncology Products
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you have any questions, please call me at (301) 796-0876.

Sincerely,

{See appended electronic signature page}

Frank H. Cross, Jr.
Co-Chief, Project Management Staff
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Frank Cross
9/11/2007 01:18:29 PM



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville, MD 20857

NDA 22-234

NDA ACKNOWLEDGMENT

Hospira, Inc.
Attention: Mary Pontikes
Senior Associate, Global Regulatory Affairs
275 N. Field Drive
D-0389, Bldg H2-2N
Lake Forest, IL 60045-5046

Dear Ms. Pontikes:

We have received your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Docetaxel Injection, 10mg/mL Vials

Review Priority Classification: Standard (S)

Date of Application: July 9, 2007

Date of Receipt: July 11, 2007

Our Reference Number: NDA 22-234

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on September 9, 2007, in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be May 11, 2007.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have not fulfilled the requirements. We acknowledge receipt of your request for a waiver of pediatric studies for this application. Once the application has been filed we will notify you whether we have waived the pediatric study requirement for this application.

Please cite the NDA number listed above at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

NDA 22-234

Page 2

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Oncology Products
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you have any questions, please call me at (301) 796-0876.

Sincerely,

{See appended electronic signature page}

Frank H. Cross, Jr.
Co-Chief, Project Management Staff
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Frank Cross

9/10/2007 03:04:07 PM

REQUEST FOR CONSULTATION

TO (Office/Division): Office of Microbiology
Attention: David Hussong, Ph.D.

FROM (Name, Office/Division, and Phone Number of Requestor):
Karl Stiller, ONDQA
x6-1993

DATE
August 22, 2007

IND NO.

NDA NO.
22-234

TYPE OF DOCUMENT
Original Submission

DATE OF DOCUMENT
July 9, 2007

NAME OF DRUG
Docetaxel Inj.

PRIORITY CONSIDERATION

CLASSIFICATION OF DRUG

DESIRED COMPLETION DATE
January 22, 2008

NAME OF FIRM: Hospira

REASON FOR REQUEST

I. GENERAL

- | | | |
|--|---|--|
| <input type="checkbox"/> NEW PROTOCOL | <input type="checkbox"/> PRE-NDA MEETING | <input type="checkbox"/> RESPONSE TO DEFICIENCY LETTER |
| <input type="checkbox"/> PROGRESS REPORT | <input type="checkbox"/> END-OF-PHASE 2a MEETING | <input type="checkbox"/> FINAL PRINTED LABELING |
| <input type="checkbox"/> NEW CORRESPONDENCE | <input type="checkbox"/> END-OF-PHASE 2 MEETING | <input type="checkbox"/> LABELING REVISION |
| <input type="checkbox"/> DRUG ADVERTISING | <input type="checkbox"/> RESUBMISSION | <input type="checkbox"/> ORIGINAL NEW CORRESPONDENCE |
| <input type="checkbox"/> ADVERSE REACTION REPORT | <input checked="" type="checkbox"/> SAFETY / EFFICACY | <input type="checkbox"/> FORMULATIVE REVIEW |
| <input type="checkbox"/> MANUFACTURING CHANGE / ADDITION | <input type="checkbox"/> PAPER NDA | <input type="checkbox"/> OTHER (SPECIFY BELOW): |
| <input type="checkbox"/> MEETING PLANNED BY | <input type="checkbox"/> CONTROL SUPPLEMENT | |

II. BIOMETRICS

- | | |
|---|---|
| <input type="checkbox"/> PRIORITY P NDA REVIEW | <input type="checkbox"/> CHEMISTRY REVIEW |
| <input type="checkbox"/> END-OF-PHASE 2 MEETING | <input type="checkbox"/> PHARMACOLOGY |
| <input type="checkbox"/> CONTROLLED STUDIES | <input type="checkbox"/> BIOPHARMACEUTICS |
| <input type="checkbox"/> PROTOCOL REVIEW | <input type="checkbox"/> OTHER (SPECIFY BELOW): |
| <input type="checkbox"/> OTHER (SPECIFY BELOW): | |

III. BIOPHARMACEUTICS

- | | |
|--|--|
| <input type="checkbox"/> DISSOLUTION | <input type="checkbox"/> DEFICIENCY LETTER RESPONSE |
| <input type="checkbox"/> BIOAVAILABILITY STUDIES | <input type="checkbox"/> PROTOCOL - BIOPHARMACEUTICS |
| <input type="checkbox"/> PHASE 4 STUDIES | <input type="checkbox"/> IN-VIVO WAIVER REQUEST |

IV. DRUG SAFETY

- | | |
|--|--|
| <input type="checkbox"/> PHASE 4 SURVEILLANCE/EPIDEMIOLOGY PROTOCOL | <input type="checkbox"/> REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY |
| <input type="checkbox"/> DRUG USE, e.g., POPULATION EXPOSURE, ASSOCIATED DIAGNOSES | <input type="checkbox"/> SUMMARY OF ADVERSE EXPERIENCE |
| <input type="checkbox"/> CASE REPORTS OF SPECIFIC REACTIONS (List below) | <input type="checkbox"/> POISON RISK ANALYSIS |
| <input type="checkbox"/> COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP | |

V. SCIENTIFIC INVESTIGATIONS

- | | |
|-----------------------------------|--------------------------------------|
| <input type="checkbox"/> CLINICAL | <input type="checkbox"/> NONCLINICAL |
|-----------------------------------|--------------------------------------|

COMMENTS / SPECIAL INSTRUCTIONS: Please review this application from a microbiology standpoint. Please note that this application contains (b) (4).

SIGNATURE OF REQUESTOR
Karl Stiller

METHOD OF DELIVERY (Check one)
 DFS EMAIL MAIL HAND

PRINTED NAME AND SIGNATURE OF RECEIVER

PRINTED NAME AND SIGNATURE OF DELIVERER

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Karl Stiller
8/22/2007 04:03:37 PM



July 9, 2007

Dr. Richard Pazdur
Director, Office of Oncology Drug Products
Center for Drug Evaluation and Research
Food and Drug Administration
Central Document Room (CDR)
5901-B Ammendale Road
Beltsville, MD 20705-1266

(b) (4)
**MICROBIOLOGY/STERILITY
ASSURANCE
DOCUMENTATION ENCLOSED**

(b) (4)
ENCLOSED

Re: Docetaxel Injection, 10 mg/mL Vials

ORIGINAL NEW DRUG APPLICATION

Hospira, Inc. hereby submits a New Drug Application (NDA) for Docetaxel Injection in accordance with Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. The basis for this submission is Sanofi-Aventis U.S., NDA # 20-449 for TAXOTERE[®] Injection Concentrate, approved on May 14, 1996.

Docetaxel Injection is presented in three fill volumes with different packaging configurations as described below:

<u>Strength</u>	<u>Fill Volume</u>	<u>Container Size</u>	<u>Dosage Form</u>
10 mg/mL	2 mL	2 mL	Injectable
10 mg/mL	8 mL	10 mL	Injectable
10 mg/mL	16 mL	20 mL	Injectable

Hospira Inc.
275 North Field Drive
Dept. 389, Bldg. H2-2
Lake Forest, IL 60045



The active ingredient, indications, route of administration, and dosage form are the same as those of the reference listed drug. The formulation of Hospira, Inc.'s Docetaxel Injection differs from that of the reference listed drug; however, the strength of Docetaxel Injection is the same as the reference listed drug after TAXOTERE[®] Injection Concentrate has been diluted to a strength of 10 mg/mL prior to addition into an infusion solution. Comparative information is contained in Module 1 (Section 1.12.12). The differences between the labeling content of the proposed drug product and that of the Reference Listed Drug, TAXOTERE[®] Injection Concentrate are noted in the side-by-side labeling comparison provided in Module 1 (Section 1.14.3.1). A high-level summary of the differences between Hospira, Inc.'s Docetaxel Injection and the Reference Listed Drug, TAXOTERE[®] Injection Concentrate, is provided below:

- Hospira, Inc.'s Docetaxel Injection can be directly diluted into infusion solutions, as compared to TAXOTERE[®] Injection Concentrate, which must be diluted to a strength of 10 mg/mL prior to addition into infusion solutions.
- The qualitative/quantitative composition of Hospira, Inc.'s Docetaxel Injection is different from the innovator.
- Hospira, Inc. is registering an additional presentation (160 mg/16 mL) that the innovator does not have.
- Hospira, Inc. is proposing a multi-dose application for the 80 mg/8 mL and 160 mg/16 mL presentations as compared to TAXOTERE[®] Injection Concentrate, which is supplied as single-dose vials.
- The labeling for Hospira, Inc.'s Docetaxel Injection differs from that of TAXOTERE Injection Concentrate, as a result of the items listed above.

The data supporting this application is provided in twelve (12) volumes and is organized according to the sections defined in the FDA's "Guidance for Industry: Submitting Marketing Applications According to the ICH-CTD Format – General Considerations" and "Guidance for Industry: M4Q: The CTD – Quality," dated August 2001. We note that Module 5 is not applicable to this NDA submission; therefore, Module 5 is not included herein.



Hospira, Inc. requests (b) (4) month expiration dating for all presentations of the subject drug product based on the enclosed accelerated and room temperature data. Hospira hereby commits that the first three (3) commercial batches of Docetaxel Injection will be placed into the stability program and evaluated at regular intervals to support the proposed expiration date. Yearly, thereafter, at least one (1) commercial batch will be placed in our stability program and the test results reported to the Agency in the annual reports.

Hospira, Inc. commits to provide samples, if requested, by the Agency and to resolve any issues identified in the method validation process after approval.

Hospira, Inc. requests a therapeutic equivalence designation of "AP" (as defined in the FDA Orange Book) for our Docetaxel Injection product upon approval of the NDA.



Hospira, Inc. hereby certifies that we have sent a complete copy of the technical section (Module 3: Quality) of this submission (designated as the "field copy") to the FDA Central Document Room.

Appended to the archival copy of this submission is a CD containing Structured Product Labeling (SPL) and Microsoft Word versions of the package insert; Draft Printed Labeling as PDFs of the proposed container labels, carton labeling and package insert; and side-by-side comparisons of Hospira, Inc.'s labeling versus the most current TAXOTERE[®] Injection Concentrate labeling. The files contained on the CD have been



scanned for viruses using the current version of McAfee VirusScan Enterprise 8.0 virus scanning software.

On February 2, 2007 Hospira, Inc. acquired Mayne Pharma Limited. This original NDA applies to Hospira, Inc. In those instances herein where there is a reference to Mayne Pharma (USA), Inc. or Mayne Pharma Limited, this should be considered as applying to Hospira, Inc.

We trust that this submission is complete. If you require any clarification or further information, please feel free to contact me.

Sincerely,

HOSPIRA, INC.

A handwritten signature in cursive script that reads "Mary Pontikes".

Mary Pontikes
Sr. Associate, Global Regulatory Affairs
Phone: (224) 212-4852
Fax: (224) 212-5401
e-mail: mary.pontikes@secure.hospira.com

61 Page(s) of Draft Labeling has been
Withheld in Full as B4 (CCI/TS)
immediately following this page